Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression - the PRIME-PRAXOL randomized controlled trial

Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression - the PRIME-PRAXOL randomized controlled trial | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression - the PRIME-PRAXOL randomized controlled trial Filip Ventorp, Jesper Lindahl, Stefan Möller, Marie Asp, Sofia Olsson, and 16 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7887410/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted You are reading this latest preprint version Abstract Here, we examined the efficacy and target engagement of dopamine agonist pramipexole in treating a cross-diagnostic sample of mood disorders characterized by severe anhedonia. Patients with major depressive disorder, dysthymia or bipolar depression, all with significant anhedonia symptoms per the Snaith-Hamilton Pleasure Scale (SHAPS), were randomized to either a flexible-dose add-on of pramipexole or placebo for nine weeks. Primary outcome was change in total SHAPS score. Accelerometers were used during the study to assess treatment-associated changes in physical activity. 7-Tesla functional magnetic resonance imaging (fMRI) with the Monetary Incentive Delay task was used to investigate reward related neural response in the ventral striatum before and after treatment. Mixed models were used to investigate between-group differences in symptom improvement. In the intention-to-treat sample (pramipexole: n=41; placebo: n=41) the mean decrease in SHAPS score from baseline to week 9 in the pramipexole group was 6.5 points compared to 2.4 in the placebo group yielding a between-group difference in mean change of 4.1 (p=0.005, Hedge's g=0.63). Pramipexole was superior to placebo on several of the secondary outcomes related to anhedonia and apathy. These findings were supported by accelerometry data, which showed that pramipexole significantly increased light physical activity throughout the study, compared to placebo (p<0.01, pramipexole: n=32; placebo: n=29). Adjusted mean signal intensity for reward-related activation in bilateral ventral striatum showed a significant group difference (p=0.030; Hedge's g=0.32, pramipexole: n=25; placebo: n=23). In patients receiving pramipexole (but not placebo) there was a trend suggesting that greater reductions in anhedonic symptoms were associated with increased treatment-related activation in the ventral striatum in response to reward cues. (rho=–0.38, p=0.060). Drop-out rate was 6% and the intervention was generally well tolerated with no serious adverse events. These findings demonstrate that pramipexole is an efficacious and safe add-on option for treating anhedonia in mood disorders. This treatment not only alleviates subjective symptoms of anhedonia but also objectively boosts light physical activity and increases activation in the brain's reward system. These findings suggest that pramipexole effectively targets the neurocircuits involved in motivation and reward. ClinicalTrials.gov identifier: NCT05355337. Health sciences/Biomarkers/Predictive markers Health sciences/Diseases/Psychiatric disorders/Depression Health sciences/Health care/Therapeutics/Drug therapy/Combination drug therapy Figures Figure 1 Figure 2 Figure 3 Introduction Mood disorders, such as depressive and bipolar disorders, have become the leading causes of disability worldwide with enormous negative impact on society and the affected individuals 1 . Remission rates are low and residual symptoms, such as anhedonia, frequently persists after treatment, representing one of the most debilitating and common challenges in recovery 2 . Currently, the selection of antidepressant treatments lacks objective measures, such as symptom profiles or biomarkers, to guide decision-making. Clinicians therefore often resort to trial-and-error methods which can be time-consuming and less effective. The pursuit for precision in antidepressant treatments might be limited by a strict adherence to the categorical definitions of depressive disorders in diagnostic manuals when selecting participants for randomized controlled trials (RCTs). This approach may not fully capture the considerable clinical, and likely pathophysiological, heterogeneity of depression, leading to generic treatment recommendations rather than focusing on specific depression endophenotypes 3 . Anhedonia — the reduced motivation or ability to experience pleasure — has emerged as a depression endophenotype of pivotal clinical relevance that can be targeted by specific mechanism-based treatments 4 . Symptoms of anhedonia extend beyond major depressive disorder (MDD), with similar symptoms in bipolar depressive episodes and dysthymia. Anhedonia predicts poor response to pharmacological, psychological and neurostimulation treatments, worse disease course, and increased suicide risk 5,6 thus representing a critically important unmet need. Clinical manifestations of anhedonia, including low motivation and reduced reward-seeking behavior, are assumed to be caused by dysregulation of reward processing within the brain. Central to this is the mesolimbic dopamine pathway, projecting from the ventral tegmental area to the ventral striatum 7 . Dopamine agonism has been proposed as a potential treatment target for a depression subtype marked by severe anhedonia 8,9 . The dopamine receptor D3, with high expression levels in the nucleus accumbens of the ventral striatum, has emerged as a promising target for such therapies. Pramipexole, a dopamine agonist with high affinity for the D3 receptor, is commonly used in Parkinson's disease (PD) and alleviates not only motor symptoms but also anhedonia in PD patients 10 . Long-term administration of pramipexole leads to desensitization of dopamine autoreceptors and an increase in dopaminergic neurotransmission 11 , potentially normalizing a reduced "dopaminergic tone" which may be a mechanism of anhedonic depression 9 . Pramipexole has shown robust antidepressant effects in individuals with treatment resistant depression (TRD) 12 and clinical observations indicate that it ameliorates anhedonia in this patient group, with greater benefit observed at higher doses 8 . A pilot study conducted by our group provided preliminary evidence suggesting an anti-anhedonic effect of pramipexole 9 which was partly supported by a recent RCT 12 . In this transdiagnostic RCT, we investigated the efficacy of high dose pramipexole on anhedonia and related symptoms in mood disorders. Patients with MDD, dysthymia, or bipolar depression, all with significant anhedonia at baseline, were randomized to receive pramipexole or placebo, added to ongoing antidepressant or mood stabilizing medication, for nine weeks. Primary outcome was change in the total score on the Snaith-Hamilton Pleasure Scale (SHAPS) 13 . Secondary clinical outcomes included both expert- and self-rating scales, which assessed a wide range of depression-related symptoms. Accelerometers were used to provide objective measures of treatment-associated changes in physical activity. We also aimed to demonstrate target engagement of pramipexole on reward-related neurocircuitry in the ventral striatum using fMRI in conjunction with the Monetary Incentive Delay (MID) task before and after treatment. Together, these multimodal assessments were designed to provide a comprehensive evaluation of pramipexole’s clinical efficacy and mechanistic effects on anhedonia. Results Participants The flow of study participants is summarized in Fig. 1. A total of 125 patients underwent screening and 87 fulfilled eligibility criteria. Two eligible participants withdrew consent before baseline, leading to 85 patients being randomized, 43 to pramipexole and 42 to placebo. All patients had a main diagnosis of MDD, dysthymia or bipolar disorder with a current depressive episode and significant anhedonia defined as 3 or 4 points on ≥ 3 items on the SHAPS 13 . In this nine-week RCT, participants had either flexible dose pramipexole or identical placebo added to their ongoing, stable treatment of antidepressant or mood-stabilizing medication Two participants did not reach week 3 and therefore had no post-baseline symptom data and were consequently excluded from the analysis. One of these participants (placebo group) discontinued due to adverse events and poor compliance, and one of these participants (pramipexole group) discontinued due to an allergic reaction that was later assessed as unrelated to pramipexole. One participant (pramipexole group) met the eligibility criteria at screening but not at baseline. Despite this, this subject was randomized but later confirmed by the external monitor to be ineligible for the study and was therefore excluded from the analysis. Another two participants had at least one post-baseline assessment but dropped out before week 9 (end of study). Both were included in the intention-to-treat (ITT) analyses. One of these patients (placebo) dropped out after week 3 due to personal reasons and the other patient (placebo) was withdrawn from the study after week 6 since he abruptly discontinued his regular antidepressant medication without informing the study team, which deviated from the protocol. Eighty-two participants with at least one post-baseline data point were included in the ITT sample. Demographic and clinical characteristics are summarized in Table 1. Mean (SD) age was 47.22 (13.66) with no significant difference between pramipexole and placebo groups (p=0.89). Thirty-seven (45.12%) of the participants were female and the groups did not differ significantly with regards to gender distribution (p=0.82). Most study participants were diagnosed with MDD, comprising 63.41% of the pramipexole group and 56.10% of the placebo group, for an overall prevalence of 59.76%. Dysthymia was the primary diagnosis for 34.15% of participants receiving pramipexole and 41.46% in the placebo group, totaling 37.80% across the sample. A small proportion (2.44%) in each group was diagnosed with bipolar disorder with a current depressive episode. Concomitant medication use was comparable between groups, except for SNRIs, which were more frequently used in the placebo group (χ² test, p = 0.031). Compliance was evaluated using a journal in which study participants recorded each day that pramipexole or placebo was taken according to the dose titration schedule. Pill counts were also carried out systematically at each scheduled visit to assess compliance. A patient had 100% compliance if they had taken the study intervention at each day in the correct dose. Mean compliance was above 96.47% at each treatment visit. Table 1. Demographics and clinical characteristics for participants with at least one post-baseline assessment (ITT sample, n=82). Data are expressed as mean (standard deviation, SD) or as percentages. The endpoint dosage is reported for participants who reached the study endpoint (n=80). Abbreviations: ECT, Electroconvulsive Therapy; BMI, Body Mass Index; SSRI, Selective Serotonin Reuptake Inhibitors; SNRI, Serotonin-Norepinephrine Reuptake Inhibitors; NDRI, Norepinephrine-Dopamine Reuptake Inhibitors; TCA, Tricyclic Antidepressants; SHAPS, Snaith-Hamilton Pleasure Scale; HDRS-6, Hamilton Depression Rating Scale - 6-item version; MADRS-S, Montgomery-Åsberg Depression Rating Scale – Self-report version; DARS, Dimensional Anhedonia Rating Scale; AES-S, Apathy Evaluation Scale – Self-report version; GAD-7, Generalized Anxiety Disorder 7-item Scale; ISI, Insomnia Severity Index; BBQ, Brunnsviken Brief Quality of Life Scale. Planned statistical analysis Mixed-model repeated measures (MMRM) analyses were conducted in the ITT sample, adjusting for baseline values to assess treatment efficacy. Pairwise comparisons between treatment groups at each time point were performed on change scores (delta from baseline), using estimated marginal means (EMMs) derived from the fitted mixed-effects model. Missing data from dropouts were imputed using last observation carried forward (LOCF). Least-squares means, 95% confidence intervals, model estimates, p-values, and effect sizes (Hedges’ g) for the primary and secondary outcomes are presented in the Extended Data Table 2. For clinical rating scales, data were collected from baseline, week 3, week 6 and week 9. Because no treatment effect was expected before week 3, accelerometry data were analyzed using both data from all weeks and models excluding weeks 1 and 2. For the fMRI results, a mixed-effects model was applied using the two available timepoints, with pairwise comparisons conducted on the endpoint raw values (rather than on change scores). Primary outcome At baseline, SHAPS scores were comparable between groups (pramipexole: mean=41.54, SD=5.57; placebo: mean=39.51, SD=5.16; t=1.71, p=0.092). Over the course of the trial, SHAPS scores decreased more in the pramipexole group than in the placebo group (Fig. 2A and Extended Data Table 1). By endpoint (week 9), mean scores were 34.98 (SD=8.04) in the pramipexole group and 37.20 (SD=7.25) in the placebo group. In the MMRM analysis, there was a significant main effect of treatment (p=0.0049), indicating that pramipexole produced greater overall improvement in SHAPS scores compared with placebo across weeks 3–9. Pairwise comparisons of the EMM showed significant differences favoring pramipexole at all three timepoints, Fig. 2A. At the 9-week primary endpoint, the estimated mean decrease in SHAPS score from baseline in the pramipexole group was 6.5 points compared to 2.4 in the placebo group (Extended Data Table 2). The difference in mean change was -4.1 (95% CI: -6.9 to -1.2, p=0.005, Hedge's g=0.63). Analysis without LOCF including only completed data yielded similar results (mean difference -4.0, 95% CI: -6.9 to -1.2, p=0.006, Hedge's g=0.62). Secondary outcomes Rating Scales After nine weeks of treatment, pramipexole led to significant improvements in anhedonia and apathy symptoms measured by the Dimensional Anhedonia Rating Scale, DARS (p=0.007, Hedge's g=0.60) and by the Apathy Evaluation Scale – Self rapport version, AES-S (p<0.001, Hedge's g=0.75), relative to placebo. The effects of pramipexole appeared to be more pronounced for motivational symptoms, as it did not lead to significant improvements in broader depression measures at the endpoint. At week 9, there were no significant differences between pramipexole and placebo on the Montgomery-Åsberg Depression Rating Scale self-rating (MADRS-S) (p=0.11, Hedge's g=0.35) or the Hamilton Depression Rating Scale 6-item subscale, HDRS-6 (p=0.08, Hedge's g=0.39). However, when analyzing data across all three post-baseline time points, pramipexole showed a significant main effect on both MADRS-S (p=0.012) and HDRS-6 (p=0.0018), indicating an overall benefit of pramipexole over placebo on depressive symptoms. Similarly, no significant treatment effect were observed at week 9 on the Generalized Anxiety Disorder 7-item scale, GAD-7 (p=0.33, Hedge's g =0.22), the Insomnia Severity Index, ISI (p=0.81, Hedge's g=0.05), or the Brunnsviken Brief Quality of Life scale, BBQ (p=0.10, Hedge's g=0.37). Sensitivity analyses including only full data without LOCF yielded similar results. In the pramipexole group, 39% showed a ≥50% improvement in SHAPS scores, and 22% (n=9) achieved complete remission of anhedonia symptoms. Complete descriptive and statistical summaries are provided in Extended Data Table 1 and Table 2, respectively. Light Physical Activity Light Physical activity (LPA), expressed as average minutes per day, was quantified using accelerometry, providing an objective measure of engagement in daily physical activities at different intensities 14 . Change scores of LPA are depicted in Fig. 2B. Additional accelerometry outcomes, including awake time, sedentary time (SED), and moderate-to-vigorous physical activity (MVPA), are shown in Extended Data Fig. E1, and information on wear time and valid periods is provided in the Supplementary Data Fig 1. Consistent with our hypotheses, there was a significant main effect of treatment (p=0.0039) in the MMRM analysis, which included all nine weeks, indicating that pramipexole produced greater overall improvement in LPA delta scores compared with placebo. A follow-up model excluding early-phase data (weeks 1 and 2) revealed an even stronger treatment effect (p=0.0005). Pairwise comparisons of the estimated marginal means revealed significant advantage for pramipexole at week 4 (p=0.022), week 5 (p=0.001), and week 7 (p=0.012), with Hedges’ g values ranging from 0.58 to 0.85. Across the four time points when the rating scales were administered, LPA values showed no significant correlation with SHAPS scores (p=0.18), suggesting that these measures reflect distinct dimensions of anhedonia or related behavioral patterns. Reward-related BOLD activity response in the ventral striatum Reward-related brain activity was assessed before and after treatment using 7T-fMRI and a simplified version of the Monetary Incentive Delay (MID) task. All participants were invited to take part in the fMRI sub-study. Forty-eight participants (pramipexole: n=25; placebo: n=23) were included in the fMRI analysis. Several exclusions were made for reasons such as refusal to participate, medical contraindications such as implants or surgical history incompatible with the Imaging Center’s safety protocols, and technical difficulties encountered during the scanning. The participants included in the fMRI analyses were comparable between the groups in terms of mean age and sex distribution. Specifically, the mean age was 43.88 years in the pramipexole group and 47.91 years in the placebo group, with women accounting for 40.00% and 43.48% of each group, respectively. To estimate reward-related brain activity we extracted the mean BOLD signal from a bilateral ventral striatum region of interest (see Fig. 3) during the anticipation phase for high-reward vs low-reward trials for all participants pre- and post-treatment. Subsequently, we estimated marginal means for each group and timepoint using a mixed model and these adjusted means were used for group comparisons. For this contrast, we observed a significant group difference (p=0.030, Hedge’s g=0.32), indicating a preserved reward-related activity in the pramipexole group compared with decreased ventral striatum activity in the placebo group (Fig. 3). Within the pramipexole group we observed a trend towards a significant negative correlation between treatment response (change in SHAPS score between baseline and week 9) and treatment-associated change in reward-related activity (rho=-0.38, p=0.060); this suggests that larger reductions in anhedonia were associated with greater reward-related brain activity in the ventral striatum. A non-significant positive correlation was observed in the placebo group (rho=0.29, p=0.18). Blinding integrity Participants who reached week 9 were asked to guess the allocation arm, with response options: 'placebo', 'pramipexole', or 'unsure'. A binomial test was performed to assess whether participants in the active treatment arm correctly identified their allocation more often than expected by chance. In the pramipexole group, 43.90% correctly identified their allocation, while 36.59 % guessed placebo and 19.51% were unsure. This proportion did not differ significantly from the 50% expected under random guessing (p=0.53) indicating that participants in the pramipexole group were not better than chance at identifying their treatment, supporting effective blinding. However, in the placebo group, 66.66% correctly guessed they were allocated to placebo, 20.51% guessed pramipexole, and 12.82% were unsure. The proportion approached significance (p=0.053) indicating a tendency toward better-than-chance guessing in the placebo group. Safety and tolerability All patients randomized to either pramipexole or placebo (n=85) were included in the safety population for which adverse events (AEs) are summarized in Supplementary Table 1. There were no serious adverse events in any of the groups. Pramipexole was generally well-tolerated with only one patient dropping out due to AEs. This AE (suspected allergic reaction) was later assessed as not related to pramipexole. The overall incidence of any adverse event was high in both groups, but several specific events were more frequent in the pramipexole group. The most prominent differences were seen for sleep disturbances (72.09% vs. 33.33%), nausea (60.47% vs. 14.29%), dizziness (32.59% vs. 4.76%), fatigue (46.51% vs. 30.95%), and anxiety (30.23% vs. 7.14%). In contrast, some adverse events such as nightmares (16% vs. 2%) were more often reported in the placebo group. At six time points during the course of the study, patients self-reported selected and modified items from the Young Ziegler Mania Rating Scale (M-YMRS), the Problem Gambling Severity Index (M-PGSI) and the Questionnaire for Impulsive-Compulsive Disorders in Parkinson´s Disease (M-QUIP) (see Supplementary Table 2). If patients self-reported any such symptoms, they were further evaluated by the study physician for clinical significance. Two patients in the pramipexole group (both diagnosed with dysthymia at baseline) developed mild manic symptoms including decreased need for sleep, increased energy and flight of ideas. For one of the patients these symptoms resolved after dose decrease and the patient successfully completed the study at a low dose (0.52 mg). The other patient displayed only mild symptoms and continued dose escalation according to plan. This patient completed the study, and the manic symptoms resolved following pramipexole discontinuation after the study. There were no significant between-group differences on the M-PGSI, highlighting no evidence that pramipexole increased gambling risk in this patient sample. According to the M-QUIP, at week 3, significantly more patients in the pramipexole group (25.58%) reported difficulties in controlling buying compared to the placebo group (4.76%). This difference was not seen at either week 6 or week 9 (prevalence between 4.76-6.98% at both time points, similar between groups). Symptoms related to impulse control were not assessed to be of sufficient intensity or severity to withdraw any of patients from the study, and no patients opted to drop out due to any impulse control related symptoms. Typically, the dose was decreased or dose escalation stopped during the emergence of any of these symptoms. Discussion In this study, we demonstrate that dopamine agonist pramipexole is an efficacious and safe augmentation strategy for treating anhedonia symptoms in mood disorders. We specifically included patients exhibiting significant anhedonia, and our findings align with existing evidence linking reduced dopaminergic activity to this particular symptom of depression 15 . Our study mainly supports the results from several observational studies 16 and a recent randomized clinical trial (RCT) 12 but critically extend these findings by providing new mechanistic insights on pramipexole’s antidepressant effect. Specifically, we demonstrate its engagement with the brain's reward system, highlighting its targeted action. Moreover, this is the first RCT for antidepressants that included objective measures of physical activity as outcomes. Our findings reveal that pramipexole not only alleviated self-reported symptoms of anhedonia but also objectively increased physical activity. These results suggest that incorporating objective outcome measures, such as accelerometry data, into antidepressant trials holds promising potential for future research Browning et al. recently showed that pramipexole is efficacious in treating general depressive symptoms as well as anhedonia in treatment-resistant (unipolar) MDD 12 . While Browning et al. established the efficacy of pramipexole in treatment-resistant MDD, our study suggests that pramipexole may also be a viable treatment option for less resistant MDD cases as well as dysthymia, if anhedonia is a prominent symptom. We included patients with MDD, dysthymia, or bipolar depression, irrespective of overall depression severity, focusing on those with significant anhedonia. Our study set a lower threshold for treatment resistance compared to Browning et al., requiring only one previous antidepressant treatment without remission. Despite this criterion, our participants had undergone an average of four different antidepressant treatments and five depressive episodes over their lifetimes, indicating a generally difficult-to-treat cohort. Clinical experience suggests that pramipexole is more efficacious in patients with a symptom profile of anhedonia and low energy 8 . This observation is consistent with the mechanistic link between such symptoms, reward-related behaviors and decreased dopaminergic activity in the mesocorticolimbic reward circuit 17-19 . In line with the tenets of the Research Domain Criteria initiative 20 , we used a transdiagnostic design enrolling patients across a depressive spectrum, but all of whom displayed significant anhedonia at baseline. Although this is the first pramipexole study using this methodology, a similar dimensional and cross-diagnostic recruitment strategy was used by Krystal et al. in their RCT evaluating the anti-anhedonic effects of kappa receptor antagonist aticaprant 21 . Our study therefore contributes to a growing body of research advocating for dimensional, mechanism-based antidepressant treatment strategies that go beyond traditional diagnostic categories. Of note, both the Krystal et al. 21 and our study found that antidepressant treatments known to directly (pramipexole) or indirectly (aticaprant) boost dopaminergic signaling improved anhedonia, as well as reward-related ventral striatal activation, while having smaller effects on overall depression severity. This dissociation underscores the importance of targeted treatments (and sample stratification) depending on clinical manifestation of depressive disorders rather than taking a one-fits-all approach that solely relies on global depression severity. More generally, our study design differed from most previous antidepressant trials by using the SHAPS, an anhedonia-specific measure, rather than a composite depression rating scale like the HDRS or MADRS as the primary outcome measure. Moreover, only patients with relatively higher baseline SHAPS score were included in the study. This is an example of predictive enrichment and demonstrates the value of selecting outcome measures that directly align with the tested drug's mechanism of action, strategies that are increasingly recognized as means to advance precision treatment of depression 22 . By targeting a specific endophenotype of depression – in this case "anhedonic depression" - which we hypothesized was more likely to respond to pramipexole, we aimed to address some of the heterogeneity that has challenged antidepressant treatment research 23 . Significant anhedonia occurs in at least half of depression 24 and is a major barrier to functional recovery and often persists despite the resolution of other depressive symptoms with conventional treatments 25 . Our findings suggest that pramipexole may be used as a targeted treatment for clinical anhedonia across a spectrum of depressive disorder diagnoses offering a symptom-focused therapeutic approach. Our study demonstrates that adding pramipexole to standard treatment for depressed patients with anhedonia led to increased physical activity. While accelerometers are commonly used to quantify higher levels of physical activity, in our study they served to examine whether anhedonia-related sedentary behavior could be shifted toward greater engagement in everyday activities, even at low levels of physical exertion (light physical activity and awake time). Although self-reports and expert ratings of depressive symptoms provide valuable information as outcome measures, they are inherently subjective and potentially biased. Wearable technologies, on the other hand, offer a more objective approach to assessing treatment outcomes, potentially overcoming these limitations by providing continuous real-world data 26 . Our study is the first antidepressant RCT to incorporate objective wearable measures alongside traditional symptom ratings. These findings not only validate the clinical efficacy of pramipexole but also demonstrate the value of using multi-modal assessment approaches. We observed that pramipexole promotes a healthier pattern of daily activity, reflected in increased movements and longer wakefulness. ‍ Some case reports have noted instances of excessive exercise behavior in Parkinson’s disease (PD) patients taking pramipexole 27 , but we did not observe any concerning patterns of excessive exercise in the current study. Pramipexole was generally well tolerated, with no serious adverse events reported. Only one participant discontinued due to an adverse event, which was ultimately deemed to be unrelated to pramipexole. The overall dropout rate was very low (6%), further underscoring the tolerability of the intervention. This high level of tolerability may in part be attributable to the relatively slower titration schedule applied in the trial 8 . Although the overall incidence of adverse events was high in both groups, several specific symptoms occurred more frequently in the pramipexole arm, including sleep disturbances, nausea, dizziness, fatigue, and anxiety. Importantly, the majority of these were mild to moderate in severity and manageable with dose adjustments. Two patients in the pramipexole group developed mild manic symptoms, both of whom successfully completed the trial following either dose reduction or study completion and subsequent drug discontinuation. Regarding impulse control dysregulation, pramipexole was not associated with increased risk of gambling. However, there was a temporary rise in self-reported difficulties with controlling of buying behaviors, which did not persist over time. None of the impulse control–related symptoms led to withdrawal. Collectively, these findings support the overall safety and tolerability of pramipexole in patients with mood disorders, while emphasizing the importance of careful monitoring for dopaminergic side effects such as hypomania, sleep disturbance, and impulse-control symptoms. While pramipexole demonstrates efficacy and tolerability as an adjunctive antidepressant, its optimal placement within the treatment algorithm remains to be determined. Based on our results and the recent RCT by Browning et al. 12 effect sizes of pramipexole compares favorably to those of other commonly used antidepressants. A recent randomized open-label trial in treatment resistant depression demonstrated that pramipexole augmentation was superior to quetiapine, a commonly prescribed second-generation antipsychotic for this condition 28 . These results suggest that pramipexole should be considered a highly prioritized treatment option for depressive states in mood disorder. In further support of implementing pramipexole in treatment guidelines a recent health economic analysis suggested that pramipexole is a cost-effective intervention for bipolar disorder 29 . Pramipexole is also a clear example of drug repositioning, which is both a cost-effective and de-risked approach 30 , as the tolerability and safety profile is known from previous use in PD and restless legs syndrome. Not all previous RCTs using pramipexole for depression have demonstrated strong effects. This variability might be due to several factors, such as differences in the target population and dosing strategies. Recognizing that some previous RCTs might have used insufficient doses, we implemented a flexible dosing strategy. This approach allowed participants in our study to achieve a higher mean end-dose of pramipexole compared to some other trials 31,32 . Clinical experience suggests that relatively higher doses of pramipexole are needed for optimal efficacy, especially for older individuals since dopamine receptors may decrease with age 33 . Animal studies suggest that low pramipexole doses affects pre-synaptic dopaminergic autoreceptors, whereas higher doses are needed for postsynaptic effects 34 . Although higher doses of pramipexole resulted in greater improvements in anhedonia, we also observed a clear and robust separation between pramipexole and placebo groups in several outcome measures already after three weeks of treatment. These findings suggest that pramipexole may be efficacious at relatively lower doses, but careful dose titration might be needed to reach a relatively higher dose for greatest efficacy. In the present study, we observed a significant group difference in ventral striatal activation during the MID task, indicating treatment-related modulations of reward-related neural activity by pramipexole. Consistent with the findings by Krystal et al. 21 , the placebo group in our study exhibited a decrease in reward-related ventral striatal activation, while this effect was relatively preserved in the pramipexole group. The reduction in ventral striatal activity in the placebo group might be attributed to a habituation effect from repeated MID task testing, an effect potentially counteracted by dopamine agonism. 35 Notably, reduced ventral striatal activation in the MID task has been demonstrated in individuals with MDD, supporting its relevance as a neural marker of anhedonia and motivational deficits 36 . In the present study, we found that changes in ventral striatal activation were correlated with improvements in anhedonia at trend level, indicating that individuals showing greater clinical benefit might also exhibited stronger engagement of this reward-related region. These findings are consistent with the notion that pramipexole may help to normalize reward- and motivation-related neural function. To our knowledge, this is among the first studies in depression to experimentally evaluate the impact of a dopaminergic intervention on reward-related neural circuitry. Taken together, the fMRI results offer important evidence of neural target engagement by pramipexole and indicate that modulation of ventral striatal function during reward processing may underlie its therapeutic effects on anhedonia. Our study comes with some limitations. Notably, two-thirds of the patients in the placebo group correctly guessed their allocation, while blinding was effectively maintained in the pramipexole group. This discrepancy could introduce expectancy effects, potentially leading to bias in subjective symptom reporting. However, a key strength of our study is the inclusion of more objective outcome measures, such as accelerometry data, which helps mitigate the risk of bias and adds robustness to our findings. In conclusion, this RCT demonstrates that the dopamine agonist pramipexole is an efficacious, safe, and well-tolerated augmentation strategy for patients with mood disorders characterized by anhedonia. By enriching for a clinically well-defined phenotype of anhedonic depression and employing both traditional symptom ratings and objective multimodal outcome measures, we provide converging evidence that pramipexole improves not only subjective reports of anhedonia, but also objective indices of daily functioning and reward-related neural activity. Methods Comprehensive information on the study protocol has been pre-published 37 . Patient Population Patients were recruited via ads or clinical referrals from psychiatric or primary care units. They were pre-screened via telephone and then screened on site to determine if they fulfilled eligibility criteria. Briefly, patients with major depressive disorder (MDD), dysthymia or bipolar disorder with a current depressive episode were randomized to receive either add-on flexible dose pramipexole or identical placebo for nine weeks. All patients had significant anhedonia which was defined as 3 or 4 points on ≥3 items on the SHAPS 13 . This recruitment strategy is consistent with anhedonia as a cross-diagnostic symptom with a tentative common pathophysiology involving reward circuitry alterations and low dopaminergic activity. Study participants underwent psychiatric and somatic evaluations including standard lab screening. Primary diagnoses were determined through diagnostic interviews conducted by psychiatry residents or specialists, combining relevant sections of the structured Mini International Neuropsychiatric Interview (MINI) with a review of each patient's clinical history 38 . All participants had ongoing treatment with one or several antidepressants or mood stabilizers ≥4 weeks and had tried at least one antidepressant at a therapeutic dose without remission. Key exclusion criteria were ongoing substance abuse, a diagnosis of psychotic disorder, known emotionally unstable personality disorder, ADHD with hyperactivity, or impulse control disorder and acute suicidal risk. Participants were excluded if they took medications that affect pramipexole blood levels of pramipexole or have similar/antagonistic mechanisms of action as pramipexole. One exception was quetiapine ≤ 150 mg/day as the binding to dopamine receptors at such doses is low 39 . Full eligibility criteria are given in Supplementary Table 3. Trial design This was an academic single-center trial conducted in Lund, Sweden from February 2023 through June 2025. The primary outcome measure was absolute change in the SHAPS total score between baseline and week 9, calculated using the Likert scale (1–4 points per item, total scores 14 to 56). All patients were asked to wear an accelerometer during the trial period with the option to opt out if inconvenient. An optional fMRI sub-study (at 7T) including the MID task, was conducted at baseline and week 9 in a subset of participants, who received monetary compensation for participation. Intervention Extended release pramipexole tablets from STADA Nordic were labelled and repackaged consistent with EU guidelines and good manufacturing practice (GMP). Identical placebo tablets were produced by Ardena in line with Good Manufacturing Practice. Pramipexole tablets were taken once daily, preferable at nighttime. Patients, research physicians and nurses involved in patient assessments were blind for treatment allocation. Placebo or active treatment was placed in boxes designated for each patient by unblinded staff not involved in symptom assessments. Blinded study personnel then administrated these to the patients using flexible dosing schedule (Supplementary Table 4). Clinical Studies Sweden Forum South established the randomization list. At the week 9 visit, after clinical ratings, patients were asked if they believe they had been allocated to pramipexole or placebo. At the start of the study, participants only had two options: pramipexole or placebo. During the study, several patients described their guess as a “coin-toss”. We therefore added the possibility of answering “unsure”. We used individually tailored dose titration schedule based on recommended dose escalation strategies for Parkinson’s disease but adjusted according to side effects and efficacy (see Supplementary Table 4). We increased pramipexole doses weekly and decreased the dose in the event of intolerable side effects and waited approximately one week before a new attempt of dose escalation was made. If patients had a Clinical Global Impression (CGI) – Severity score of ≤ 2, dose escalation was stopped for the remainder of the study and if patients did not have increased symptom burden at subsequent study visits. Assessments Rating scales The Snaith-Hamilton Pleasure Scale (SHAPS) 40 was scored from 1 to 4 on each item with a total score of 56. The SHAPS is a commonly used self-rating scale that mainly covers the consummatory phase of anhedonia. Response (≥50% reduction in SHAPS scores) was evaluated using both the Likert scoring method (1–4 points per item) and the original dichotomized method (1–2=0, 3–4=1). Remission was defined only according to the dichotomized scoring method. We used the self-rating version of Montgomery-Åsberg Depression Rating Scale (MADRS-S), and response was defined as ≥50% improvement and remission as ≤10 41 at week 9. The Hamilton Depression Rating Scale – 6-item version (HDRS-6) 42 is an expert-rating-scale including six core depression items from the HDRS – “depressed mood”, “feelings of guilt”, “work and interest”, “psychic anxiety”, “general somatic symptoms”, and “retardation”. This subscale has shown higher sensitivity for antidepressant signals than the full HDRS 43 . In addition to the SHAPS, anhedonia was also evaluated using the Dimensional Anhedonia Rating Scale (DARS) 44 as it includes additional anhedonia domains and separates the motivational and consummatory phases of anhedonia. The Apathy Evaluation Scale (AES-S) is a self-rating scale evaluating apathy symptoms which are conceptually related to anhedonia. Although this scale has mainly been used in populations with neurodegenerative disorders, it has also been used for depression 45 . Generalized anxiety symptoms were assessed with the Generalized Anxiety Disorder 7-item scale (GAD-7) 46 , a 7-item self-report scale widely validated for screening and severity rating of generalized anxiety disorder. Insomnia symptoms were evaluated with the Insomnia Severity Index (ISI) 47 , a 7-item self-report measure of perceived insomnia severity and its impact on daily functioning. Quality of life was measured with the Brunnsviken Brief Quality of Life Scale BBQ 48 , a brief self-report instrument developed and validated in Sweden for assessing subjective well-being across multiple life domains. Accelerometry Physical activity (PA) outcomes were assessed using accelerometers (ActiGraph GT3X-BT; ActiGraph, Pensacola, Florida, USA) as further described in the study protocol 37 . The accelerometers were initialized to sample three-dimensional acceleration data at 30 Hz, with ActiGraph’s idle sleep mode enabled. Study participants were instructed to wear the accelerometer day and night for 10 weeks in total, at the non-dominant wrist. The first week was used as a baseline measure before the intervention started. During the remaining nine weeks, raw data were extracted every third week using the Actilife software version 6.13.4 (ActiGraph LLC). The data were extracted as gt3x-files and processed in R (version 4.5.0) with the R package GGIR (version 3.2.6) as previously described 49 . Data were aggregated using the Euclidean Norm Minus One g (ENMO) 50 metric and averaged over one-second epochs. A day was considered valid if it included at least 16 hours of wear time across the full 24-hour period and covered a minimum of two-thirds of waking hours 51 . Non-wear and awake time were estimated using the default algorithms in GGIR 50,52 . Data were analyzed for weekly PA. Patients having less than four valid days during one of the weeks did not reach the valid week criteria and were excluded from PA analyses at that timepoint, consistent with established practice 14 . To estimate sedentary time (SED) and PA at various intensities during awake time, ENMO cut-points developed for the non-dominant wrist by Hildebrand et al. 53,54 were applied (SED 100.6 mg). For PA analysis, a measurement day was defined as the period from wake-up to wake-up. A configuration file with all settings used for GGIR data processing is available as Supplementary Data S1. fMRI and Monetary Incentive Delay Task To assess treatment effects on ventral striatal activity during reward anticipation, we employed a simplified Monetary Incentive Delay Task (MID) task focusing on appetitive processing 9,55,56 . The task design followed earlier simplified incentive delay paradigms: on each trial, participants viewed one of two cues signaling either a high (€0.50) or low (€0.01) potential reward. Reward delivery depended on response speed to a subsequent target cue, with rewards administered on 75–80% of trials. Scans were acquired using a 7T whole body MR scanner (Philips Achieva, Philips Medical Systems, Best, The Netherlands) using a 32-channel head coil (Nova Medical, Wilmington, MA, USA). Anatomical 3D T1-weighted images were acquired with the following parameters (repetition time (TR)=5.0 ms, echo time (TE)=1.97 ms, inversion time (TI)=1200 ms, shot interval=3500 ms, Turbo factor=450, flip angle=6°, voxel size=1.0×1.0×1.0 mm3). blood-oxygen-level-dependent (BOLD) fMRI was collected using a simultaneous multi-slice echo-planar imaging (SMS-EPI) sequence with parameters (TR=1500 ms, TE=25 ms, flip angle 55°, voxel size=2.0×2.0×2.0 mm3, slice gap=0.2 mm, slices=50, multi-slice acceleration factor=2, SENSE acceleration factor=3). In addition, a FLAIR sequence (TR=6000 ms, TE=316 ms, TI=1825 ms, flip angle 55°, voxel size=1.0×1.0×1.0 mm3) was acquired and read by an experienced neuroradiologist; no relevant lesions were detected. Moderate white matter lesions believed to represent small vessel disease were present in 2 individuals (placebo 1, pramipexole 1) and more severe in 1 individual (pramipexole). Preprocessing was performed using fMRIPrep 23.1.4 57 (RRID:SCR_016216), which is based on Nipype 1.8.6 58 (RRID:SCR_002502). See Supplementary Data S2 for details. Modelling of BOLD activity was performed using SPM12 (SPM12, fil.ion.ucl.ac.uk/spm/software/spm12). Volumes were first smoothed using a 6 mm FWHM Gaussian filter. First level models were then estimated for each individual and session with 6 movement parameters as well as onsets and durations of all stimuli presentations (high-reward and low-reward cues and outcomes, target presentation and reward anticipation) convolved with the canonical haemodynamic response function from SPM12. The contrast between activity during the anticipation phase for high reward cues vs. low reward cues was used for group level analysis. For each participant, average activation statistics were extracted from a bilateral region of interest (ROI) encompassing the ventral striatum (see Fig. 3) before and after treatment. The ROI was created using the Accumbens region from the probabilistic Harvard-Oxford Subcortical Atlas. Given the spatial uncertainty of fMRI activation patterns, we chose to use a liberal definition of this brain region by employing non-thresholded ROI similar to a previous study by Krystal et al. 21 . Safety assessments To evaluate adverse events related to impulsivity, gambling behavior, and mood instability, we extracted relevant self-rating items from the QUIP 59 , the PGSI 60 , and the YMRS 61 . Modifications were implemented to reduce administration time and improve compatibility, and the prefix ‘M-’ was added to each scale to denote these changes. Study physicians reviewed self-ratings of these items and if there were positive responses, conducted interviews to determine if these symptoms were of clinical relevance. M-QUIP: The original QUIP contains four domains assessing different impulsive-compulsive behaviors. In our adaptation, the final question from each domain, specifically targeting Parkinson-related medication, was removed. Additionally, the entire fourth domain concerning hobbyism (behavioral addictions) and punding (non-goal-oriented and repetitive behaviors) was excluded. Furthermore, the response format was simplified by reducing the number of response options from five to four. M-PGSI: In the modified PGSI, items 3, 4, 6, and 8 were omitted to avoid repetition. The remaining items were retained in their original format. M-YMRS: The YMRS was adapted both in structure and mode of administration. Items 3, 7, 9, and 11 were excluded. Additionally, the scale was administered as a self-report rather than through clinician interview, and the number of response options per item was reduced from five to four. Oversight The study was pre-registered at clinicaltrials.gov (ref# NCT05355337). The study was approved by the Swedish Ethical Review Authority (reference number 2023-01927-02) and the Swedish Medical Products Agency (EudraCT 2022-001563-26). Clinical Studies Sweden Forum South monitored the study in accordance with Good Clinical Practice. Patients signed an informed consent form after receiving oral and written information about the study. The Department of Psychiatry at Skåne University Hospital was sponsor. Statistical Analyses A statistical analysis plan was uploaded at clinicaltrials.gov prior to statistical analyses. An independent statistician performed the analyses of the primary and secondary outcomes that were assessed using rating scales. In our power calculation, we estimated an effect size for pramipexole of 0.27, based on reports from other antidepressant studies 62 . This corresponds to a clinically significant MADRS score improvement of approximately 4 points, which aligns with a ≥ 4-point change on the SHAPS. We based the correlation coefficient between repeated MADRS measures on data from our previous pilot study (r = 0.5). To achieve 80% power with an alpha of .05, we initially calculated that 74 participants were necessary. Considering an estimated 5% dropout rate from our pilot data, we aimed to recruit 80 participants to start treatment. A prespecified interim analysis was conducted by an independent statistician in June 2024. The number of dropouts was controlled, and the sample size was recalculated with an updated standard deviation. Based on these results, the recruitment target was increased by five participants. 80 patients with complete efficacy data through week 9 were needed. Statistical analyses of longitudinal outcome data were conducted using mixed models for repeated measures, including fixed effects; treatment group (placebo vs. pramipexole), time (week), and their interaction (group × time) plus the baseline value of the respective outcome to adjust for individual differences at study entry. The unstructured covariance structure was chosen. Hedges’ g’s effect size was calculated. The analyses were performed on data with missing values replaced by last-observation-carried forward (LOCF), but also on data with missing values. Non-parametric correlation analyses (Spearman) were conducted to examine associations between ventral striatal activation and SHAPS change scores. IBM SPSS Statistics version 28 and 30 (IBM Corporation, Armonk, NY, USA), SAS Enterprise Guide 8.3 with SAS Proc mixed and R (version 4.5.0) with nlme (v3.1-168) and emmeans package (v 1.11.2-8) were used. The statistical significance level was set to p < 0.05. Declarations Data availability The datasets generated and analyzed during this study contain sensitive personal information and are protected under the European Union General Data Protection Regulation (GDPR). For this reason, individual-level clinical data cannot be made publicly available. De-identified data that support the findings of this study may be available from the corresponding author upon reasonable request, contingent upon approval from the relevant institutional ethics committee and compliance with GDPR and local data protection regulations. Funding The study has received funding from the Swedish Research Council (grant number 2020-01428), Swedish governmental funding of clinical research (ALF), grants from the province of Scania, Olle Engkvist Foundation (grant number 214-0363), the Crafoord Foundation (grant number 20220522), the Brain Foundation (FO2022-0050 & FO2025-0058-HK-168), Ellen and Henrik Sjöbring Foundation, Söderström – Königska Foundation (grant number SLS-969692), Region Kronoberg, Bror Gadelius Foundation, John Hains Foundation, Per-Eric and Ulla Schyberg’s Foundation, OM Persson Foundation, Foundation for Mental Health, grants from the Department of Psychiatry Skåne University Hospital, and Sten K. Johnson Foundation. This was an academic trial and funders had no role in designing or conducting the trial. Acknowledgements We would like to express our sincere gratitude to research coordinator Johanna Larsson and research nurses Jeanette Tindholt, Sara Helgesson, and Kajsa Jönsson for their support in participant coordination and data collection. We also thank Ann-Sofi Svensson for her invaluable assistance with study logistics and administration. We also acknowledge statistician Helene Jacobsson and data manager Andre Wennersten for their contributions to the study. The National 7T facility at Lund University Bioimaging Center is gratefully acknowledged for providing experimental resources. We acknowledge support from Philips Clinical Science. Disclosures Dr Lindqvist has received speaking honorarium from H. Lundbeck AB and Janssen-Cilag AB. Dr Asp has received speaking honorarium from H. Lundbeck AB. Over the past 3 years, Dr. Pizzagalli has received consulting fees from Arrowhead Pharmaceuticals, Boehringer Ingelheim, Circular Genomics, Compass Pathways, Engrail Therapeutics, Karla Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, and Neuroscience Software; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) and Alkermes; he has received research funding from the Bird Foundation, Brain and Behavior Research Foundation, Dana Foundation, Millennium Pharmaceuticals, NIMH, and Wellcome Leap; he has received stock options from Ceretype Neuromedicine, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. All other authors have no conflicts of interest or relevant disclosures. All views expressed are solely those of the authors. References Cassano, P. & Fava, M. Depression and public health: an overview. J Psychosom Res 53 , 849-857 (2002). Serretti, A. Anhedonia: Current and future treatments. PCN Rep 4 , e70088 (2025). Hyman, S.E. The diagnosis of mental disorders: the problem of reification. Annu Rev Clin Psychol 6 , 155-179 (2010). Hasler, G., Drevets, W.C., Manji, H.K. & Charney, D.S. Discovering endophenotypes for major depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 29 , 1765-1781 (2004). Pizzagalli, D.A. Anhedonia: Preclinical, Translational, and Clinical Integration , (2022). Pizzagalli, D.A. Toward a Better Understanding of the Mechanisms and Pathophysiology of Anhedonia: Are We Ready for Translation? Am J Psychiatry 179 , 458-469 (2022). Der-Avakian, A. & Markou, A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci 35 , 68-77 (2012). Fawcett, J. , et al. Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression. Am J Psychiatry 173 , 107-111 (2016). Ventorp, F. , et al. Preliminary Evidence of Efficacy and Target Engagement of Pramipexole in Anhedonic Depression. Psychiatr Res Clin Pract 4 , 42-47 (2022). Lemke, M.R., Brecht, H.M., Koester, J., Kraus, P.H. & Reichmann, H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 17 , 214-220 (2005). Chernoloz, O., El Mansari, M. & Blier, P. Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. J Psychiatry Neurosci 37 , 113-121 (2012). Browning, M. , et al. Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK. Lancet Psychiatry (2025). Snaith, R.P. , et al. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 167 , 99-103 (1995). Migueles, J.H. , et al. Accelerometer Data Collection and Processing Criteria to Assess Physical Activity and Other Outcomes: A Systematic Review and Practical Considerations. Sports Med 47 , 1821-1845 (2017). Treadway, M.T. & Salamone, J.D. Vigor, Effort-Related Aspects of Motivation and Anhedonia. Curr Top Behav Neurosci 58 , 325-353 (2022). Tundo, A. , et al. Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis. Life (Basel) 13 (2023). Ferenczi, E.A. , et al. Prefrontal cortical regulation of brainwide circuit dynamics and reward-related behavior. Science 351 , aac9698 (2016). Hoflich, A., Michenthaler, P., Kasper, S. & Lanzenberger, R. Circuit Mechanisms of Reward, Anhedonia, and Depression. Int J Neuropsychopharmacol 22 , 105-118 (2019). Argyropoulos, S.V. & Nutt, D.J. Anhedonia revisited: is there a role for dopamine-targeting drugs for depression? J Psychopharmacol 27 , 869-877 (2013). Insel, T. , et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 167 , 748-751 (2010). Krystal, A.D. , et al. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating kappa-opioid antagonism as a treatment for anhedonia. Nat Med 26 , 760-768 (2020). Miller, A.H. , et al. Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry. Brain Behav Immun 125 , 319-329 (2025). Fried, E.I. Moving forward: how depression heterogeneity hinders progress in treatment and research. Expert Rev Neurother 17 , 423-425 (2017). Whitton, A.E. & Pizzagalli, D.A. Anhedonia in Depression and Bipolar Disorder. Curr Top Behav Neurosci 58 , 111-127 (2022). Nutt, D. , et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 21 , 461-471 (2007). Fedor, S. , et al. Wearable Technology in Clinical Practice for Depressive Disorder. N Engl J Med 389 , 2457-2466 (2023). Vitale, C. , et al. Exercise dependence induced by pramipexole in Parkinson's Disease-a case report. Mov Disord 25 , 2893-2894 (2010). Mishra, B.R. , et al. Comparative efficacy of antidepressant augmentation with amantadine vs pramipexole in treatment-resistant unipolar depression: A randomised controlled trial. J Affect Disord 390 , 119891 (2025). Berger, M. , et al. Cost-effectiveness of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression: Economic evaluation of the PAX-BD randomised controlled trial. J Affect Disord 391 , 119937 (2025). Fava, M. The promise and challenges of drug repurposing in psychiatry. World Psychiatry 17 , 28-29 (2018). Franco-Chaves, J.A. , et al. Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study. J Affect Disord 149 , 319-325 (2013). Cusin, C. , et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry 74 , e636-641 (2013). Wang, G.J. , et al. Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. Life Sci 56 , PL249-253 (1995). Maj, J., Rogoz, Z., Skuza, G. & Kolodziejczyk, K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol 324 , 31-37 (1997). Knutson, B. & Greer, S.M. Anticipatory affect: neural correlates and consequences for choice. Philos Trans R Soc Lond B Biol Sci 363 , 3771-3786 (2008). Pizzagalli, D.A. , et al. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry 166 , 702-710 (2009). Lindahl, J. , et al. Add-on pramipexole for anhedonic depression: study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden. BMJ Open 13 , e076900 (2023). Sheehan, D.V. , et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 Suppl 20 , 22-33;quiz 34-57 (1998). Nord, M. , et al. Comparison of D(2) dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. Int J Neuropsychopharmacol 14 , 1357-1366 (2011). Nakonezny, P.A., Carmody, T.J., Morris, D.W., Kurian, B.T. & Trivedi, M.H. Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder. Int Clin Psychopharmacol 25 , 328-333 (2010). Thase, M.E., Mahableshwarkar, A.R., Dragheim, M., Loft, H. & Vieta, E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol 26 , 979-993 (2016). Bech, P. , et al. Quantitative rating of depressive states. Acta Psychiatr Scand 51 , 161-170 (1975). Hieronymus, F., Emilsson, J.F., Nilsson, S. & Eriksson, E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry 21 , 523-530 (2016). Rizvi, S.J. , et al. Development and validation of the Dimensional Anhedonia Rating Scale (DARS) in a community sample and individuals with major depression. Psychiatry Res 229 , 109-119 (2015). Marin, R.S., Biedrzycki, R.C. & Firinciogullari, S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 38 , 143-162 (1991). Spitzer, R.L., Kroenke, K., Williams, J.B. & Löwe, B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166 , 1092-1097 (2006). Bastien, C.H., Vallières, A. & Morin, C.M. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2 , 297-307 (2001). Lindner, P. , et al. The Brunnsviken Brief Quality of Life Scale (BBQ): Development and Psychometric Evaluation. Cogn Behav Ther 45 , 182-195 (2016). Migueles, J., Rowlands, A., Huber, F., Sabia, S. & van Hees, V. GGIR: A Research Community–Driven Open Source R Package for Generating Physical Activity and Sleep Outcomes From Multi-Day Raw Accelerometer Data. Journal for the Measurement of Physical Behaviour 2 , 188-196 (2019). van Hees, V.T. , et al. Separating movement and gravity components in an acceleration signal and implications for the assessment of human daily physical activity. PLoS One 8 , e61691 (2013). Migueles, J.H. , et al. Comparability of accelerometer signal aggregation metrics across placements and dominant wrist cut points for the assessment of physical activity in adults. Sci Rep 9 , 18235 (2019). van Hees, V.T. , et al. Estimating sleep parameters using an accelerometer without sleep diary. Sci Rep 8 , 12975 (2018). Hildebrand, M., VT, V.A.N.H., Hansen, B.H. & Ekelund, U. Age group comparability of raw accelerometer output from wrist- and hip-worn monitors. Med Sci Sports Exerc 46 , 1816-1824 (2014). Hildebrand, M., Hansen, B.H., van Hees, V.T. & Ekelund, U. Evaluation of raw acceleration sedentary thresholds in children and adults. Scand J Med Sci Sports 27 , 1814-1823 (2017). Knutson, B., Westdorp, A., Kaiser, E. & Hommer, D. FMRI visualization of brain activity during a monetary incentive delay task. Neuroimage 12 , 20-27 (2000). Jensen, J. , et al. Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron 40 , 1251-1257 (2003). Esteban, O. , et al. fMRIPrep: a robust preprocessing pipeline for functional MRI. Nat Methods 16 , 111-116 (2019). Gorgolewski, K. , et al. Nipype: a flexible, lightweight and extensible neuroimaging data processing framework in python. Front Neuroinform 5 , 13 (2011). Weintraub, D. , et al. Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. Mov Disord 27 , 242-247 (2012). Ferris, J.W., H. . The Canadian Problem Gambling Index: Final Report. (Canadian Centre on Substance Abuse (CCSA), Ottawa, 2001). Young, R.C., Biggs, J.T., Ziegler, V.E. & Meyer, D.A. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133 , 429-435 (1978). Cipriani, A. , et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391 , 1357-1366 (2018). Additional Declarations Yes there is potential Competing Interest. Over the past 3 years, Dr. Pizzagalli has received consulting fees from Arrowhead Pharmaceuticals, Boehringer Ingelheim, Circular Genomics, Compass Pathways, Engrail Therapeutics, Karla Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, and Neuroscience Software; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) and Alkermes; he has received research funding from the Bird Foundation, Brain and Behavior Research Foundation, Dana Foundation, Millennium Pharmaceuticals, NIMH, and Wellcome Leap; he has received stock options from Ceretype Neuromedicine, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. Dr Lindqvist has received speaking honorarium from H. Lundbeck AB and Janssen-Cilag AB. Dr Asp has received speaking honorarium from H. Lundbeck AB. Supplementary Files SupplementaryTable1AE1.docx Supplementary table 1 SupplementaryTable2AERating1.docx Supplementary table 2 SupplementaryTable3Eligibility.docx Supplementary table 3 SupplementaryTable4.docx Supplementary table 4 SupplementaryDataFigure1ValidationAnalysisofAccelorometerDataDOC.docx Supplementary Data Fig 1 SupplementaryDataS1ConffileGGIRdata.csv Supplementary Data S1 SupplementaryDataS2PreprocMethod.docx Supplementary Data S2 ExtendedData.docx Cite Share Download PDF Status: Under Review Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7887410","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":532351485,"identity":"b3dd6a9a-0855-41d5-9e65-d0ba164fb60d","order_by":0,"name":"Filip Ventorp","email":"","orcid":"","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Filip","middleName":"","lastName":"Ventorp","suffix":""},{"id":532351486,"identity":"bdd97ea9-6a11-41df-98f1-de4ac7ee772e","order_by":1,"name":"Jesper Lindahl","email":"","orcid":"","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Jesper","middleName":"","lastName":"Lindahl","suffix":""},{"id":532351487,"identity":"49f9232a-7a0a-4607-a42b-047254534fe9","order_by":2,"name":"Stefan Möller","email":"","orcid":"https://orcid.org/0000-0001-9144-4077","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Stefan","middleName":"","lastName":"Möller","suffix":""},{"id":532351488,"identity":"a838607f-42b7-4ce9-bd61-12c72a531ad6","order_by":3,"name":"Marie Asp","email":"","orcid":"","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Marie","middleName":"","lastName":"Asp","suffix":""},{"id":532351489,"identity":"f2e3bf87-2d34-4580-a268-b9159695cc68","order_by":4,"name":"Sofia Olsson","email":"","orcid":"","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Sofia","middleName":"","lastName":"Olsson","suffix":""},{"id":532351490,"identity":"7415c888-2a4a-4e59-81da-7fd84cc13d75","order_by":5,"name":"Martina Svensson","email":"","orcid":"","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Martina","middleName":"","lastName":"Svensson","suffix":""},{"id":532351491,"identity":"27ef04d0-c2ea-4fc4-a011-bab633d66a21","order_by":6,"name":"Filip Ängeby","email":"","orcid":"","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Filip","middleName":"","lastName":"Ängeby","suffix":""},{"id":532351492,"identity":"031955ab-20ac-4f2f-8d32-558b25f4afec","order_by":7,"name":"Armida Pravdinske","email":"","orcid":"","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Armida","middleName":"","lastName":"Pravdinske","suffix":""},{"id":532351493,"identity":"cbbacdb8-a74a-40df-b38d-314c5329e3b4","order_by":8,"name":"Johanna Tjernberg","email":"","orcid":"","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Johanna","middleName":"","lastName":"Tjernberg","suffix":""},{"id":532351494,"identity":"220b9b99-f616-4581-88bf-8a7498d5b4d1","order_by":9,"name":"Susann Schrey","email":"","orcid":"","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Susann","middleName":"","lastName":"Schrey","suffix":""},{"id":532351495,"identity":"35c78866-b527-4940-b08a-39c4c6e1def3","order_by":10,"name":"Darya Ståhl","email":"","orcid":"","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Darya","middleName":"","lastName":"Ståhl","suffix":""},{"id":532351496,"identity":"07249cd4-b37b-4491-a524-e3b2143c47e8","order_by":11,"name":"Viktor Magnusson","email":"","orcid":"","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Viktor","middleName":"","lastName":"Magnusson","suffix":""},{"id":532351497,"identity":"b3209019-9362-4765-9fe4-429dd6b61c2e","order_by":12,"name":"Emilia Eliasson","email":"","orcid":"https://orcid.org/0009-0003-7265-2438","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Emilia","middleName":"","lastName":"Eliasson","suffix":""},{"id":532351498,"identity":"75fa5701-8e07-41b0-b6d8-c973fb4a597f","order_by":13,"name":"Danielle van Westen","email":"","orcid":"https://orcid.org/0000-0001-8649-9874","institution":"Center for Medical Imaging and Physiology, Skane University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Danielle","middleName":"van","lastName":"Westen","suffix":""},{"id":532351499,"identity":"5bace069-2468-46c7-830d-ad34595f8d98","order_by":14,"name":"Tomas Deierborg","email":"","orcid":"","institution":"Lund Universitet","correspondingAuthor":false,"prefix":"","firstName":"Tomas","middleName":"","lastName":"Deierborg","suffix":""},{"id":532351500,"identity":"01156782-06cd-4253-b966-6297800d90a1","order_by":15,"name":"Kristoffer Månsson","email":"","orcid":"https://orcid.org/0000-0002-7796-8445","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Kristoffer","middleName":"","lastName":"Månsson","suffix":""},{"id":532351501,"identity":"79085056-5b5d-49b4-a334-e5cc7027e437","order_by":16,"name":"Diego Pizzagalli","email":"","orcid":"https://orcid.org/0000-0002-7772-1143","institution":"University of California, Irvine","correspondingAuthor":false,"prefix":"","firstName":"Diego","middleName":"","lastName":"Pizzagalli","suffix":""},{"id":532351502,"identity":"e0c09da5-b564-4641-86a1-1cb13561ff2b","order_by":17,"name":"Åsa Hammar","email":"","orcid":"","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Åsa","middleName":"","lastName":"Hammar","suffix":""},{"id":532351503,"identity":"c3d9575f-02e4-4d1c-af64-7aeb80b21099","order_by":18,"name":"Åsa Tornberg","email":"","orcid":"https://orcid.org/0000-0001-5617-0728","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Åsa","middleName":"","lastName":"Tornberg","suffix":""},{"id":532351504,"identity":"16d7a199-f275-441e-b4f2-f4fb2bb0ae80","order_by":19,"name":"Johannes Björkstrand","email":"","orcid":"","institution":"Lund University","correspondingAuthor":false,"prefix":"","firstName":"Johannes","middleName":"","lastName":"Björkstrand","suffix":""},{"id":532351484,"identity":"e3cb3679-6b4c-4bf0-829e-2ca24d76641c","order_by":20,"name":"Daniel Lindqvist","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABFElEQVRIie2PsWrDMBCGBQVPol7PpNSvcMFgDCnkVQQGdxFtIEsm19AhSx9AkKHPkDeQEbSLS7ci8NLuGTyVDhkqqYWUIGfuoA/phkPf6T9CAoF/yNxcSRaERYSgO7HpgOmMMm2sggcFksYqOK6gdJUwV+0HtnNaeX5p5WCU88n9tqeLus7eVKsJKpKuG7/S3bBW2GAXT8sZRQV5X5WFVbCTI8E4KmoV4HkiUBqF5+AUYH7ldYdqf1BqyDa3n05JH9/9iuZ24I8CA54BTnjkFKL960/FDtsHkyGCalkMqBLRV1nB8Jpi5w82j3k2fK2u7lJRbjXb13G8KT/0sJpdpmv/+r/An2ox8+mp90diIBAIBI74BuDAWQ8hNtMBAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0002-3472-327X","institution":"Lund University","correspondingAuthor":true,"prefix":"","firstName":"Daniel","middleName":"","lastName":"Lindqvist","suffix":""}],"badges":[],"createdAt":"2025-10-17 14:00:41","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7887410/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7887410/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":94632439,"identity":"eca6fa2d-22bc-4f35-b8a1-4b036c472a01","added_by":"auto","created_at":"2025-10-29 06:29:31","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":149690,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003eFlow chart illustrating the progression of participants through each stage of the trial and the reasons for screening failures (n=38) and dropouts (n=5). All participants (n=274) were first pre-screened by telephone before proceeding to the on-site screening visit (n=125). Note that a single screening may fail for multiple reasons. The analyses were conducted on an intention-to-treat basis, including two participants with at least one post-baseline evaluation who dropped out before the week 9 visit. Their data were included in the final analysis using the last observation carried forward (LOCF) method. The diagram also shows the number of participants who underwent successful 7-Tesla fMRI scans at baseline and after 9 weeks of intervention. During the study, a subset of participants wore accelerometers to track their physical activity levels. Clinical assessments, including rating scales, were performed at baseline, week 3, week 6, and at week 9 (endpoint). \u003c/em\u003eAbbreviations: \u003cem\u003eAES-S, Apathy Evaluation Scale – Self-report version; BBQ, Brunnsviken Brief Quality of Life Scale; DARS, Dimensional Anhedonia Rating Scale; GAD-7, Generalized Anxiety Disorder 7-item scale; HDRS-6, Hamilton Depression Rating Scale – 6-item version; ISI, Insomnia Severity Index; MADRS-S, Montgomery-Åsberg Depression Rating Scale – Self-report version; SHAPS, Snaith-Hamilton Pleasure Scale.\u003c/em\u003e\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-7887410/v1/bc83e0bf021ed4e3353f43af.png"},{"id":94632443,"identity":"3b48e5ee-48a3-4724-97d4-b6e37ec0c17f","added_by":"auto","created_at":"2025-10-29 06:29:31","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":452107,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003eLongitudinal changes from baseline in SHAPS scores (panel A) and light physical activity levels (panel B). Mean changes from baseline in SHAPS total scores and Light Physical Activity (LPA; mean minutes per day) are illustrated over a 9-week period for participants receiving either pramipexole (purple line, n=41) or placebo (black line, n=41). Mean dosages of pramipexole and placebo (in mg, salt form) at each timepoint are presented in panel A. Valid LPA data were available for n=29 (placebo) and n=32 (pramipexole) participants per treatment arm across all time points (LOCF applied). Group means are represented by solid lines, with shaded ribbons indicating ±1 standard error. Asterisks indicate timepoints where pairwise comparisons from mixed model revealed statistically significant differences (p\u0026lt;0.05 and \u0026lt;0.01).\u003c/em\u003e\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-7887410/v1/1a3aa0b81de0e0bd70a1f237.png"},{"id":94632442,"identity":"b8183311-d5b2-41c0-858f-48a6994a5748","added_by":"auto","created_at":"2025-10-29 06:29:31","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":222624,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003eBar plots show the adjusted means of BOLD activation in the bilateral ventral striatum for participants receiving pramipexole (n=25) or placebo (n=23). Pairwise comparisons of estimated marginal means from a repeated measures mixed model confirmed the hypothesis that ventral striatal activation was greater from pre- to post-treatment in the pramipexole group than in the placebo group (p = 0.030). To the right, representative anatomical brain images illustrate the bilateral ventral striatum regions of interest used in the analysis. Error bars Indicating +1 standard error. Asterisks indicate timepoints where pairwise comparisons from mixed model revealed statistically significant differences (p\u0026lt;0.05).\u003c/em\u003e\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-7887410/v1/2aae742aee4c904de01ab9b0.png"},{"id":106403302,"identity":"758bad19-3ad1-445c-baff-f3919a51542f","added_by":"auto","created_at":"2026-04-08 09:14:02","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1928160,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7887410/v1/3d421719-6346-4c81-8938-ece365111cc5.pdf"},{"id":94632438,"identity":"982b9c6d-0863-4ee9-8c61-672d51fc2a10","added_by":"auto","created_at":"2025-10-29 06:29:31","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":28105,"visible":true,"origin":"","legend":"Supplementary table 1","description":"","filename":"SupplementaryTable1AE1.docx","url":"https://assets-eu.researchsquare.com/files/rs-7887410/v1/ff44994ced98ec169aebfa15.docx"},{"id":94632444,"identity":"b3cc9821-9b87-4fd0-a64a-997c2224b4ea","added_by":"auto","created_at":"2025-10-29 06:29:31","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":34742,"visible":true,"origin":"","legend":"Supplementary table 2","description":"","filename":"SupplementaryTable2AERating1.docx","url":"https://assets-eu.researchsquare.com/files/rs-7887410/v1/b84ac8e9c27cc5f3004b5ab9.docx"},{"id":94640201,"identity":"aaef2971-c761-4f04-ab8f-edd4dd3716c9","added_by":"auto","created_at":"2025-10-29 07:48:44","extension":"docx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":18294,"visible":true,"origin":"","legend":"Supplementary table 3","description":"","filename":"SupplementaryTable3Eligibility.docx","url":"https://assets-eu.researchsquare.com/files/rs-7887410/v1/a581079cd44e2a2ef150b5ce.docx"},{"id":94632440,"identity":"4fba30e8-e6c7-4818-9901-b4dbfc39884f","added_by":"auto","created_at":"2025-10-29 06:29:31","extension":"docx","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":16193,"visible":true,"origin":"","legend":"Supplementary table 4","description":"","filename":"SupplementaryTable4.docx","url":"https://assets-eu.researchsquare.com/files/rs-7887410/v1/a5f23699f7ceccf8df4f6e1f.docx"},{"id":94632448,"identity":"9a8a067c-94dd-4cf4-a7fd-ca767972968b","added_by":"auto","created_at":"2025-10-29 06:29:31","extension":"docx","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":54644,"visible":true,"origin":"","legend":"\u003cp\u003eSupplementary Data Fig 1\u003c/p\u003e","description":"","filename":"SupplementaryDataFigure1ValidationAnalysisofAccelorometerDataDOC.docx","url":"https://assets-eu.researchsquare.com/files/rs-7887410/v1/5b3bf229bef989861d18dde5.docx"},{"id":94632445,"identity":"f19d780b-cabc-45af-9958-503a76a9e8bf","added_by":"auto","created_at":"2025-10-29 06:29:31","extension":"csv","order_by":6,"title":"","display":"","copyAsset":false,"role":"supplement","size":9717,"visible":true,"origin":"","legend":"Supplementary Data S1","description":"","filename":"SupplementaryDataS1ConffileGGIRdata.csv","url":"https://assets-eu.researchsquare.com/files/rs-7887410/v1/57284d87f2317c0be6ddd43e.csv"},{"id":94632452,"identity":"fc6e776f-4afc-480a-82f3-d9a1cdd3a0f9","added_by":"auto","created_at":"2025-10-29 06:29:31","extension":"docx","order_by":7,"title":"","display":"","copyAsset":false,"role":"supplement","size":17975,"visible":true,"origin":"","legend":"Supplementary Data S2","description":"","filename":"SupplementaryDataS2PreprocMethod.docx","url":"https://assets-eu.researchsquare.com/files/rs-7887410/v1/f862da61251934636c22effe.docx"},{"id":94632453,"identity":"dafe2f79-49ea-48da-a4a0-3112b6b3b71a","added_by":"auto","created_at":"2025-10-29 06:29:31","extension":"docx","order_by":8,"title":"","display":"","copyAsset":false,"role":"supplement","size":513032,"visible":true,"origin":"","legend":"","description":"","filename":"ExtendedData.docx","url":"https://assets-eu.researchsquare.com/files/rs-7887410/v1/22f6a3e84aea00b93e7ad64f.docx"}],"financialInterests":"\u003cb\u003eYes\u003c/b\u003e there is potential Competing Interest.\nOver the past 3 years, Dr. Pizzagalli has received consulting fees from Arrowhead Pharmaceuticals, Boehringer Ingelheim, Circular Genomics, Compass Pathways, Engrail Therapeutics, Karla Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, and Neuroscience Software; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) and Alkermes; he has received research funding from the Bird Foundation, Brain and Behavior Research Foundation, Dana Foundation, Millennium Pharmaceuticals, NIMH, and Wellcome Leap; he has received stock options from Ceretype Neuromedicine, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. \r\n\r\n \r\n\r\nDr Lindqvist has received speaking honorarium from H. Lundbeck AB and Janssen-Cilag AB.\r\n\r\nDr Asp has received speaking honorarium from H. Lundbeck AB.","formattedTitle":"Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression - the PRIME-PRAXOL randomized controlled trial","fulltext":[{"header":"Introduction","content":"\u003cp\u003eMood disorders, such as depressive and bipolar disorders, have become the leading causes of disability worldwide with enormous negative impact on\u0026nbsp;society and the affected individuals\u0026nbsp;\u003csup\u003e1\u003c/sup\u003e. Remission rates are low and residual symptoms, such as anhedonia, frequently persists after treatment, representing one of the most debilitating and common challenges in recovery \u003csup\u003e2\u003c/sup\u003e.\u0026nbsp;Currently, the selection of antidepressant treatments lacks objective measures, such as symptom profiles or biomarkers, to guide decision-making. Clinicians therefore often resort to trial-and-error methods which can be time-consuming and less effective. The pursuit for precision in antidepressant treatments might be limited by a strict adherence to the categorical definitions of depressive disorders in diagnostic manuals when selecting participants for randomized controlled trials (RCTs). This approach may not fully capture the considerable clinical, and likely pathophysiological,\u0026nbsp;heterogeneity of depression, leading to generic treatment recommendations rather than focusing on specific depression endophenotypes \u003csup\u003e3\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eAnhedonia — the reduced motivation or ability to experience pleasure — has emerged as a depression endophenotype of pivotal clinical relevance that can be targeted by specific mechanism-based treatments \u003csup\u003e4\u003c/sup\u003e. Symptoms of anhedonia extend beyond major depressive disorder (MDD), with similar symptoms in bipolar depressive episodes and dysthymia. Anhedonia predicts poor response to pharmacological, psychological and neurostimulation treatments, worse disease course, and increased suicide risk \u003csup\u003e5,6\u003c/sup\u003e thus representing a critically important unmet need. Clinical manifestations of anhedonia, including low motivation and reduced reward-seeking behavior, are assumed to be caused by dysregulation of reward processing within the brain. Central to this is the mesolimbic dopamine pathway, projecting from the ventral tegmental area to the ventral striatum \u003csup\u003e7\u003c/sup\u003e. Dopamine agonism has been proposed as a potential treatment target for a depression subtype marked by severe anhedonia \u003csup\u003e8,9\u003c/sup\u003e. The dopamine receptor D3, with high expression levels in the nucleus accumbens of the ventral striatum, has emerged as a promising target for such therapies. Pramipexole, a dopamine agonist with high affinity for the D3 receptor, is commonly used in Parkinson's disease (PD) and alleviates not only motor symptoms but also anhedonia in PD patients \u003csup\u003e10\u003c/sup\u003e. Long-term administration of pramipexole leads to desensitization of dopamine autoreceptors and an increase in dopaminergic neurotransmission \u003csup\u003e11\u003c/sup\u003e, potentially normalizing a reduced \"dopaminergic tone\" which may be a mechanism of anhedonic depression \u003csup\u003e9\u003c/sup\u003e. Pramipexole has shown robust antidepressant effects in individuals with treatment resistant depression (TRD) \u003csup\u003e12\u003c/sup\u003e and clinical observations indicate that it ameliorates anhedonia in this patient group, with greater benefit observed at higher doses\u0026nbsp;\u003csup\u003e8\u003c/sup\u003e. A pilot study conducted by our group provided preliminary evidence suggesting an anti-anhedonic effect of pramipexole \u003csup\u003e9\u003c/sup\u003e which was partly supported by a recent RCT\u0026nbsp;\u003csup\u003e12\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eIn this transdiagnostic RCT, we investigated the efficacy of high dose pramipexole on anhedonia and related symptoms in mood disorders. Patients with MDD, dysthymia, or bipolar depression, all with significant anhedonia at baseline, were randomized to receive pramipexole or placebo, added to ongoing antidepressant or mood stabilizing medication, for nine weeks.\u0026nbsp;Primary outcome was change in the total score on the Snaith-Hamilton Pleasure Scale (SHAPS)\u0026nbsp;\u003csup\u003e13\u003c/sup\u003e. Secondary clinical outcomes included both expert- and self-rating scales, which assessed a wide range of depression-related symptoms. Accelerometers were used to provide objective measures of treatment-associated changes in physical activity. We also aimed to demonstrate target engagement of pramipexole on reward-related neurocircuitry in the ventral striatum using fMRI in conjunction with the Monetary Incentive Delay (MID) task before and after treatment. Together, these multimodal assessments were designed to provide a comprehensive evaluation of pramipexole’s clinical efficacy and mechanistic effects on anhedonia.\u003c/p\u003e"},{"header":"Results","content":"\u003ch3\u003eParticipants\u003c/h3\u003e\n\u003cp\u003eThe flow of study participants is summarized in Fig. 1. A total of 125 patients underwent screening and 87 fulfilled eligibility criteria. Two eligible participants withdrew consent before baseline, leading to 85 patients being randomized, 43 to pramipexole and 42 to placebo. All patients had a main diagnosis of MDD, dysthymia or bipolar disorder with a current depressive episode and significant anhedonia defined as 3 or 4 points on \u0026ge; 3 items on the SHAPS \u003csup\u003e13\u003c/sup\u003e. In this nine-week RCT, participants had either flexible dose pramipexole or identical placebo added to their ongoing, stable treatment of antidepressant or mood-stabilizing medication\u003c/p\u003e\n\u003cp\u003eTwo participants did not reach week 3 and therefore had no post-baseline symptom data and were consequently excluded from the analysis. One of these participants (placebo group) discontinued due to adverse events and poor compliance, and one of these participants (pramipexole group) discontinued due to an allergic reaction that was later assessed as unrelated to pramipexole. One participant (pramipexole group) met the eligibility criteria at screening but not at baseline. Despite this, this subject was randomized but later confirmed by the external monitor to be ineligible for the study and was therefore excluded from the analysis. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAnother two participants had at least one post-baseline assessment but dropped out before week 9 (end of study). Both were included in the intention-to-treat (ITT) analyses. One of these patients (placebo) dropped out after week 3 due to personal reasons and the other patient (placebo) was withdrawn from the study after week 6 since he abruptly discontinued his regular antidepressant medication without informing the study team, which deviated from the protocol.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eEighty-two participants with at least one post-baseline data point were included in the ITT sample. Demographic and clinical characteristics are summarized in Table 1. Mean (SD) age was 47.22 (13.66) with no significant difference between pramipexole and placebo groups (p=0.89). Thirty-seven (45.12%) of the participants were female and the groups did not differ significantly with regards to gender distribution (p=0.82). Most study participants were diagnosed with MDD, comprising 63.41% of the pramipexole group and 56.10% of the placebo group, for an overall prevalence of 59.76%. Dysthymia was the primary diagnosis for 34.15% of participants receiving pramipexole and 41.46% in the placebo group, totaling 37.80% across the sample. A small proportion (2.44%) in each group was diagnosed with bipolar disorder with a current depressive episode. Concomitant medication use was comparable between groups, except for SNRIs, which were more frequently used in the placebo group (\u0026chi;\u0026sup2; test, p = 0.031).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eCompliance was evaluated using a journal in which study participants recorded each day that pramipexole or placebo was taken according to the dose titration schedule. Pill counts were also carried out systematically at each scheduled visit to assess compliance. A patient had 100% compliance if they had taken the study intervention at each day in the correct dose. Mean compliance was above 96.47% at each treatment visit.\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 1.\u003c/strong\u003e Demographics and clinical characteristics for participants with at least one post-baseline assessment (ITT sample, n=82). Data are expressed as mean (standard deviation, SD) or as percentages. The endpoint dosage is reported for participants who reached the study endpoint (n=80). Abbreviations: ECT, Electroconvulsive Therapy; BMI, Body Mass Index; SSRI, Selective Serotonin Reuptake Inhibitors; SNRI, Serotonin-Norepinephrine Reuptake Inhibitors; NDRI, Norepinephrine-Dopamine Reuptake Inhibitors; TCA, Tricyclic Antidepressants; SHAPS, Snaith-Hamilton Pleasure Scale; HDRS-6, Hamilton Depression Rating Scale - 6-item version; MADRS-S, Montgomery-\u0026Aring;sberg Depression Rating Scale \u0026ndash; Self-report version; DARS, Dimensional Anhedonia Rating Scale; AES-S, Apathy Evaluation Scale \u0026ndash; Self-report version; GAD-7, Generalized Anxiety Disorder 7-item Scale; ISI, Insomnia Severity Index; BBQ, Brunnsviken Brief Quality of Life Scale.\u003cbr\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cimg width=\"561\" height=\"931\" src=\"data:image/png;base64,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\" alt=\"A screenshot of a computerAI-generated content may be incorrect.\"\u003e\u003c/p\u003e\n\u003ch3\u003ePlanned statistical analysis\u003c/h3\u003e\n\u003cp\u003eMixed-model repeated measures (MMRM) analyses were conducted in the ITT sample, adjusting for baseline values to assess treatment efficacy. Pairwise comparisons between treatment groups at each time point were performed on change scores (delta from baseline), using estimated marginal means (EMMs) derived from the fitted mixed-effects model. Missing data from dropouts were imputed using last observation carried forward (LOCF). Least-squares means, 95% confidence intervals, model estimates, p-values, and effect sizes (Hedges\u0026rsquo; g) for the primary and secondary outcomes are presented in the Extended Data Table 2. For clinical rating scales, data were collected from baseline, week 3, week 6 and week 9. Because no treatment effect was expected before week 3, accelerometry data were analyzed using both data from all weeks and models excluding weeks 1 and 2. For the fMRI results, a mixed-effects model was applied using the two available timepoints, with pairwise comparisons conducted on the endpoint raw values (rather than on change scores).\u003c/p\u003e\n\u003ch3\u003ePrimary outcome\u003c/h3\u003e\n\u003cp\u003eAt baseline, SHAPS scores were comparable between groups (pramipexole: mean=41.54, SD=5.57; placebo: mean=39.51, SD=5.16; t=1.71, p=0.092). Over the course of the trial, SHAPS scores decreased more in the pramipexole group than in the placebo group (Fig. 2A and Extended Data Table 1). By endpoint (week 9), mean scores were 34.98 (SD=8.04) in the pramipexole group and 37.20 (SD=7.25) in the placebo group. In the MMRM analysis, there was a significant main effect of treatment (p=0.0049), indicating that pramipexole produced greater overall improvement in SHAPS scores compared with placebo across weeks 3\u0026ndash;9.\u003c/p\u003e\n\u003cp\u003ePairwise comparisons of the EMM showed significant differences favoring pramipexole at all three timepoints, Fig. 2A. At the 9-week primary endpoint, the estimated mean decrease in SHAPS score from baseline in the pramipexole group was 6.5 points compared to 2.4 in the placebo group (Extended Data Table 2). The difference in mean change was -4.1 (95% CI: -6.9 to -1.2, p=0.005, Hedge\u0026apos;s g=0.63). Analysis without LOCF including only completed data yielded similar results (mean difference -4.0, 95% CI: -6.9 to -1.2, p=0.006, Hedge\u0026apos;s g=0.62).\u003c/p\u003e\n\u003ch3\u003eSecondary outcomes\u003c/h3\u003e\n\u003ch4\u003eRating Scales\u003c/h4\u003e\n\u003cp\u003eAfter nine weeks of treatment, pramipexole led to significant improvements in anhedonia and apathy symptoms measured by the Dimensional Anhedonia Rating Scale,\u0026nbsp;DARS (p=0.007, Hedge\u0026apos;s g=0.60) and by the Apathy Evaluation Scale \u0026ndash; Self rapport version, AES-S (p\u0026lt;0.001, Hedge\u0026apos;s g=0.75), relative to placebo. The effects of pramipexole appeared to be more pronounced for motivational symptoms, as it did not lead to significant improvements in broader depression measures at the endpoint. At week 9, there were no significant differences between pramipexole and placebo on the Montgomery-\u0026Aring;sberg Depression Rating Scale self-rating (MADRS-S) (p=0.11, Hedge\u0026apos;s g=0.35) or the Hamilton Depression Rating Scale 6-item subscale, HDRS-6 (p=0.08, Hedge\u0026apos;s g=0.39). However, when analyzing data across all three post-baseline time points, pramipexole showed a significant main effect on both MADRS-S (p=0.012) and HDRS-6 (p=0.0018), indicating an overall benefit of pramipexole over placebo on depressive symptoms. Similarly, no significant treatment effect were observed at week 9 on the Generalized Anxiety Disorder 7-item scale, GAD-7 (p=0.33, Hedge\u0026apos;s g =0.22), the Insomnia Severity Index, ISI (p=0.81, Hedge\u0026apos;s g=0.05), or the Brunnsviken Brief Quality of Life scale, BBQ (p=0.10, Hedge\u0026apos;s g=0.37). Sensitivity analyses including only full data without LOCF yielded similar results.\u0026nbsp;In the\u0026nbsp;pramipexole group, 39% showed a \u0026ge;50% improvement in SHAPS scores, and 22% (n=9) achieved complete remission of anhedonia symptoms.\u003c/p\u003e\n\u003cp\u003eComplete descriptive and statistical summaries are provided in Extended Data Table 1 and Table 2, respectively.\u0026nbsp;\u003c/p\u003e\n\u003ch4\u003eLight Physical Activity\u003c/h4\u003e\n\u003cp\u003eLight Physical activity (LPA), expressed as average minutes per day, was quantified using accelerometry, providing an objective measure of engagement in daily physical activities at different intensities \u003csup\u003e14\u003c/sup\u003e. Change scores of LPA are depicted in Fig. 2B. Additional accelerometry outcomes, including awake time, sedentary time (SED), and moderate-to-vigorous physical activity (MVPA), are shown in Extended Data Fig. E1, and information on wear time and valid periods is provided in the Supplementary Data Fig 1.\u003c/p\u003e\n\u003cp\u003eConsistent with our hypotheses, there was a significant main effect of treatment (p=0.0039) in the MMRM analysis, which included all nine weeks, indicating that pramipexole produced greater overall improvement in LPA delta scores compared with placebo. A follow-up model excluding early-phase data (weeks 1 and 2) revealed an even stronger treatment effect (p=0.0005). Pairwise comparisons of the estimated marginal means revealed significant advantage for pramipexole at week 4 (p=0.022), week 5 (p=0.001), and week 7 (p=0.012), with Hedges\u0026rsquo; g values ranging from 0.58 to 0.85. Across the four time points when the rating scales were administered, LPA values showed no significant correlation with SHAPS scores (p=0.18), suggesting that these measures reflect distinct dimensions of anhedonia or related behavioral patterns.\u003c/p\u003e\n\u003ch4\u003eReward-related BOLD activity response in the ventral striatum\u003c/h4\u003e\n\u003cp\u003eReward-related brain activity was assessed before and after treatment using 7T-fMRI and a simplified version of the Monetary Incentive Delay (MID) task. All participants were invited to take part in the fMRI sub-study. Forty-eight participants (pramipexole: n=25; placebo: n=23) were included in the fMRI analysis. Several exclusions were made for reasons such as refusal to participate, medical contraindications such as implants or surgical history incompatible with the Imaging Center\u0026rsquo;s safety protocols, and technical difficulties encountered during the scanning.\u0026nbsp;The participants included in the fMRI analyses were comparable between the groups in terms of mean age and sex distribution. Specifically, the mean age was 43.88 years in the pramipexole group and 47.91 years in the placebo group, with women accounting for 40.00% and 43.48% of each group, respectively.\u003c/p\u003e\n\u003cp\u003eTo estimate reward-related brain activity we extracted the mean BOLD signal from a bilateral ventral striatum region of interest (see Fig. 3) during the anticipation phase for high-reward vs low-reward trials for all participants pre- and post-treatment. Subsequently, we estimated marginal means for each group and timepoint using a mixed model and these adjusted means were used for group comparisons. For this contrast, we observed a significant group difference (p=0.030, Hedge\u0026rsquo;s g=0.32), indicating a preserved reward-related activity in the pramipexole group compared with decreased ventral striatum activity in the placebo group (Fig. 3). \u0026nbsp;Within the pramipexole group we observed a trend towards a significant negative correlation between treatment response (change in SHAPS score between baseline and week 9) and treatment-associated change in reward-related activity (rho=-0.38, p=0.060); this suggests that larger reductions in anhedonia were associated with greater reward-related brain activity in the ventral striatum. A non-significant positive correlation was observed in the placebo group (rho=0.29, p=0.18).\u003c/p\u003e\n\u003ch3\u003eBlinding integrity\u003c/h3\u003e\n\u003cp\u003eParticipants who reached week 9 were asked to guess the allocation arm, with response options: \u0026apos;placebo\u0026apos;, \u0026apos;pramipexole\u0026apos;, or \u0026apos;unsure\u0026apos;. A binomial test was performed to assess whether participants in the active treatment arm correctly identified their allocation more often than expected by chance. In the pramipexole group, 43.90% correctly identified their allocation, while 36.59 % guessed placebo and 19.51% were unsure. This proportion did not differ significantly from the 50% expected under random guessing (p=0.53) indicating that participants in the pramipexole group were not better than chance at identifying their treatment, supporting effective blinding. However, in the placebo group, 66.66% correctly guessed they were allocated to placebo, 20.51% guessed pramipexole, and 12.82% were unsure. The proportion approached significance (p=0.053) indicating a tendency toward better-than-chance guessing in the placebo group.\u003c/p\u003e\n\u003ch3\u003eSafety and tolerability\u003c/h3\u003e\n\u003cp\u003eAll patients randomized to either pramipexole or placebo (n=85) were included in the safety population for which adverse events (AEs) are summarized in Supplementary Table 1. There were no serious adverse events in any of the groups. Pramipexole was generally well-tolerated with only one patient dropping out due to AEs. This AE (suspected allergic reaction) was later assessed as not related to pramipexole. The overall incidence of any adverse event was high in both groups, but several specific events were more frequent in the pramipexole group. The most prominent differences were seen for sleep disturbances (72.09% vs. 33.33%), nausea (60.47% vs. 14.29%), dizziness (32.59% vs. 4.76%), fatigue (46.51% vs. 30.95%), and anxiety (30.23% vs. 7.14%). In contrast, some adverse events such as nightmares (16% vs. 2%) were more often reported in the placebo group.\u003c/p\u003e\n\u003cp\u003eAt six time points during the course of the study, patients self-reported selected and modified items from the Young Ziegler Mania Rating Scale (M-YMRS), the Problem Gambling Severity Index (M-PGSI) and the Questionnaire for Impulsive-Compulsive Disorders in Parkinson\u0026acute;s Disease (M-QUIP) (see Supplementary Table 2). If patients self-reported any such symptoms, they were further evaluated by the study physician for clinical significance.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTwo patients in the pramipexole group (both diagnosed with dysthymia at baseline) developed mild manic symptoms including decreased need for sleep, increased energy and flight of ideas. For one of the patients these symptoms resolved after dose decrease and the patient successfully completed the study at a low dose (0.52 mg). The other patient displayed only mild symptoms and continued dose escalation according to plan. This patient completed the study, and the manic symptoms resolved following pramipexole discontinuation after the study.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThere were no significant between-group differences on the M-PGSI, highlighting no evidence that pramipexole increased gambling risk in this patient sample.\u003c/p\u003e\n\u003cp\u003eAccording to the M-QUIP, at week 3, significantly more patients in the pramipexole group (25.58%) reported difficulties in controlling buying compared to the placebo group (4.76%). This difference was not seen at either week 6 or week 9 (prevalence between 4.76-6.98% at both time points, similar between groups). Symptoms related to impulse control were not assessed to be of sufficient intensity or severity to withdraw any of patients from the study, and no patients opted to drop out due to any impulse control related symptoms. Typically, the dose was decreased or dose escalation stopped during the emergence of any of these symptoms.\u0026nbsp;\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this study, we demonstrate that dopamine agonist pramipexole is an efficacious and safe augmentation strategy for treating anhedonia symptoms in mood disorders.\u0026nbsp;We specifically included patients exhibiting significant anhedonia, and our findings align with existing evidence linking reduced dopaminergic activity to this particular symptom of depression\u0026nbsp;\u003csup\u003e15\u003c/sup\u003e. Our study mainly supports the results from several observational studies \u003csup\u003e16\u003c/sup\u003e and a recent randomized clinical trial (RCT)\u0026nbsp;\u003csup\u003e12\u003c/sup\u003e but critically extend these findings by providing new mechanistic insights on pramipexole’s antidepressant effect. Specifically, we demonstrate its engagement with the brain's reward system, highlighting its targeted action. Moreover, this is the first RCT for antidepressants that included objective measures of physical activity as outcomes. Our findings reveal that pramipexole not only alleviated self-reported symptoms of anhedonia but also objectively increased physical activity. These results suggest that incorporating objective outcome measures, such as accelerometry data, into antidepressant trials holds promising potential for future research\u003c/p\u003e\n\u003cp\u003eBrowning et al. recently showed that pramipexole is efficacious in treating general depressive symptoms as well as anhedonia in treatment-resistant (unipolar) MDD\u0026nbsp;\u003csup\u003e12\u003c/sup\u003e. While Browning et al. established the efficacy of pramipexole in treatment-resistant MDD, our study suggests that pramipexole may also be a viable treatment option for less resistant MDD cases as well as dysthymia, if anhedonia is a prominent symptom. We included patients with MDD, dysthymia, or bipolar depression, irrespective of overall depression severity, focusing on those with significant anhedonia. Our study set a lower threshold for treatment resistance compared to Browning et al., requiring only one previous antidepressant treatment without remission. Despite this criterion, our participants had undergone an average of four different antidepressant treatments and five depressive episodes over their lifetimes, indicating a generally difficult-to-treat cohort.\u003c/p\u003e\n\u003cp\u003eClinical experience suggests that pramipexole is more efficacious in patients with a symptom profile of anhedonia and low energy \u003csup\u003e8\u003c/sup\u003e. This observation is consistent with the mechanistic link between such symptoms, reward-related behaviors and decreased dopaminergic activity in the mesocorticolimbic reward\u0026nbsp;circuit\u0026nbsp;\u003csup\u003e17-19\u003c/sup\u003e. In line with the tenets of the Research Domain Criteria initiative\u0026nbsp;\u003csup\u003e20\u003c/sup\u003e, we used a transdiagnostic design enrolling patients across a depressive spectrum, but all of whom displayed significant anhedonia at baseline. Although this is the first pramipexole study using this methodology, a similar dimensional and cross-diagnostic recruitment strategy was used by Krystal et al. in their RCT evaluating the anti-anhedonic effects of kappa receptor antagonist aticaprant \u003csup\u003e21\u003c/sup\u003e. Our study therefore contributes to a growing body of research advocating for dimensional, mechanism-based antidepressant treatment strategies that go beyond traditional diagnostic categories. Of note, both the Krystal et al.\u0026nbsp;\u003csup\u003e21\u003c/sup\u003e and our study found that antidepressant treatments known to directly (pramipexole) or indirectly (aticaprant) boost dopaminergic signaling improved anhedonia, as well as reward-related ventral striatal activation, while having smaller effects on overall depression severity. This dissociation underscores the importance of targeted treatments (and sample stratification) depending on clinical manifestation of depressive disorders rather than taking a one-fits-all approach that solely relies on global depression severity.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eMore generally, our study design differed from most previous antidepressant trials by using\u0026nbsp;the SHAPS, an anhedonia-specific measure, rather than a composite depression rating scale like the HDRS or MADRS as the primary outcome measure. Moreover, only patients with relatively higher baseline SHAPS score were included in the study. This is an example of predictive enrichment and demonstrates the value of selecting outcome measures that directly align with the tested drug's mechanism of action, strategies that are increasingly recognized as means to advance precision treatment of depression\u0026nbsp;\u003csup\u003e22\u003c/sup\u003e.\u0026nbsp;By targeting a specific endophenotype of depression – in this case \"anhedonic depression\" - which we hypothesized was more likely to respond to pramipexole, we aimed to address some of the heterogeneity that has challenged antidepressant treatment research\u0026nbsp;\u003csup\u003e23\u003c/sup\u003e. Significant anhedonia occurs in at least half of depression\u0026nbsp;\u003csup\u003e24\u003c/sup\u003e and is a major barrier to functional recovery and often persists despite the resolution of other depressive symptoms with conventional treatments \u003csup\u003e25\u003c/sup\u003e. Our findings suggest that pramipexole may be used as a targeted treatment for clinical anhedonia across a spectrum of depressive disorder diagnoses offering a symptom-focused therapeutic approach.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eOur study demonstrates that adding pramipexole to standard treatment for depressed patients with anhedonia led to increased physical activity. While accelerometers are commonly used to quantify higher levels of physical activity, in our study they served to examine whether anhedonia-related sedentary behavior could be shifted toward greater engagement in everyday activities, even at low levels of physical exertion (light physical activity and awake time). Although self-reports and expert ratings of depressive symptoms provide valuable information as outcome measures, they are inherently subjective and potentially biased. Wearable technologies, on the other hand, offer a more objective approach to assessing treatment outcomes, potentially overcoming these limitations by providing continuous real-world data \u003csup\u003e26\u003c/sup\u003e. Our study is the first antidepressant RCT to incorporate objective wearable measures alongside traditional symptom ratings. These findings not only validate the clinical efficacy of pramipexole but also demonstrate the value of using multi-modal assessment approaches. We observed that pramipexole promotes a healthier pattern of daily activity, reflected in increased movements and longer wakefulness. ‍ Some case reports have noted instances of excessive exercise behavior in Parkinson’s disease (PD) patients taking pramipexole\u0026nbsp;\u003csup\u003e27\u003c/sup\u003e, but we did not observe any concerning patterns of excessive exercise in the current study.\u003c/p\u003e\n\u003cp\u003ePramipexole was generally well tolerated, with no serious adverse events reported.\u0026nbsp;Only one participant discontinued due to an adverse event, which was ultimately deemed to be unrelated to pramipexole.\u0026nbsp;The overall dropout rate was very low (6%), further underscoring the tolerability of the intervention. This high level of tolerability may in part be attributable to the relatively slower titration schedule applied in the trial \u003csup\u003e8\u003c/sup\u003e. Although the overall incidence of adverse events was high in both groups, several specific symptoms occurred more frequently in the pramipexole arm, including sleep disturbances, nausea, dizziness, fatigue, and anxiety. Importantly, the majority of these were mild to moderate in severity and manageable with dose adjustments. Two patients in the pramipexole group developed mild manic symptoms, both of whom successfully completed the trial following either dose reduction or study completion and subsequent drug discontinuation. Regarding impulse control dysregulation, pramipexole was not associated with increased risk of gambling.\u0026nbsp;However, there was a temporary rise in self-reported difficulties with controlling of buying behaviors, which did not persist over time.\u0026nbsp;None of the impulse control–related symptoms led to withdrawal. Collectively, these findings support the overall safety and tolerability of pramipexole in patients with mood disorders, while emphasizing the importance of careful monitoring for dopaminergic side effects such as hypomania, sleep disturbance, and impulse-control symptoms.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWhile pramipexole demonstrates efficacy and tolerability as an adjunctive antidepressant, its optimal placement within the treatment algorithm remains to be determined. Based on our results and the recent RCT by Browning et al. \u003csup\u003e12\u003c/sup\u003e effect sizes of pramipexole compares favorably to those of other commonly used antidepressants.\u0026nbsp;A recent randomized open-label trial in treatment resistant depression demonstrated that pramipexole augmentation was superior to quetiapine, a commonly prescribed second-generation antipsychotic for this condition\u0026nbsp;\u003csup\u003e28\u003c/sup\u003e. These results suggest that pramipexole should be considered a highly prioritized treatment option for depressive states in mood disorder. In further support of implementing pramipexole in treatment guidelines a recent health economic analysis suggested that pramipexole is a cost-effective intervention for bipolar disorder\u0026nbsp;\u003csup\u003e29\u003c/sup\u003e. Pramipexole is also a clear example of drug repositioning, which is both a cost-effective and de-risked approach\u0026nbsp;\u003csup\u003e30\u003c/sup\u003e, as the tolerability and safety profile is known from previous use in PD and restless legs syndrome.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eNot all\u0026nbsp;previous RCTs using pramipexole for depression have demonstrated strong effects. This variability might be due to several factors, such as differences in the target population and dosing strategies. Recognizing that some previous RCTs might have used insufficient doses, we implemented a flexible dosing strategy. This approach allowed participants in our study to achieve a higher mean end-dose of pramipexole compared to some other trials \u003csup\u003e31,32\u003c/sup\u003e.\u0026nbsp;Clinical experience suggests that relatively higher doses of pramipexole are needed for optimal efficacy, especially for older individuals since dopamine receptors may decrease with age\u0026nbsp;\u003csup\u003e33\u003c/sup\u003e. Animal studies suggest that low pramipexole doses affects pre-synaptic dopaminergic autoreceptors, whereas higher doses are needed for postsynaptic effects\u0026nbsp;\u003csup\u003e34\u003c/sup\u003e. Although higher doses of pramipexole resulted in greater improvements in anhedonia, we also observed a clear and robust separation between pramipexole and placebo groups in several outcome measures already after three weeks of treatment. These findings suggest that pramipexole may be efficacious at relatively lower doses, but careful dose titration might be needed to reach a relatively higher dose for greatest efficacy.\u003c/p\u003e\n\u003cp\u003eIn the present study, we observed a significant group difference in ventral striatal activation during the MID task, indicating treatment-related modulations of reward-related neural activity by pramipexole.\u0026nbsp;Consistent with the findings by Krystal et al. \u003csup\u003e21\u003c/sup\u003e, the placebo group in our study exhibited a decrease in reward-related ventral striatal activation, while this effect was relatively preserved in the pramipexole group. The reduction in ventral striatal activity in the placebo group might be attributed to a habituation effect from repeated MID task testing, an effect potentially counteracted by dopamine agonism.\u0026nbsp;\u003csup\u003e35\u003c/sup\u003e Notably, reduced ventral striatal activation in the MID task has been demonstrated in individuals with MDD, supporting its relevance as a neural marker of anhedonia and motivational deficits\u0026nbsp;\u003csup\u003e36\u003c/sup\u003e. In the present study, we found that\u0026nbsp;changes in ventral striatal activation were correlated with improvements in anhedonia at trend level, indicating that individuals showing greater clinical benefit might also exhibited\u0026nbsp;stronger engagement of this reward-related region. These findings are consistent with the notion that pramipexole may help to normalize reward- and motivation-related neural function. To our knowledge, this is among the first studies in depression to experimentally evaluate the impact of a dopaminergic intervention on reward-related neural circuitry. Taken together, the fMRI results offer important evidence of neural target engagement by pramipexole and indicate that modulation of ventral striatal function during reward processing may underlie its therapeutic effects on anhedonia.\u003c/p\u003e\n\u003cp\u003eOur study comes with some limitations. Notably, two-thirds of the patients in the placebo group correctly guessed their allocation, while blinding was effectively maintained in the pramipexole group. This discrepancy could introduce expectancy effects, potentially leading to bias in subjective symptom reporting. However, a key strength of our study is the inclusion of more objective outcome measures, such as accelerometry data, which helps mitigate the risk of bias and adds robustness to our findings.\u003c/p\u003e\n\u003cp\u003eIn conclusion, this RCT demonstrates that the dopamine agonist pramipexole is an efficacious, safe, and well-tolerated augmentation strategy for patients with mood disorders characterized by anhedonia. By enriching for a clinically well-defined phenotype of anhedonic depression and employing both traditional symptom ratings and objective multimodal outcome measures, we provide converging evidence that pramipexole improves not only subjective reports of anhedonia, but also objective indices of daily functioning and reward-related neural activity.\u0026nbsp;\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003eComprehensive information on the study protocol has been pre-published \u003csup\u003e37\u003c/sup\u003e.\u003c/p\u003e\n\u003ch3\u003ePatient Population\u003c/h3\u003e\n\u003cp\u003ePatients were recruited via ads or clinical referrals from psychiatric or primary care units. They were pre-screened via telephone and then screened on site to determine if they fulfilled eligibility criteria. Briefly, patients with major depressive disorder (MDD), dysthymia or bipolar disorder with a current depressive episode were randomized to receive either add-on flexible dose pramipexole or identical placebo for nine weeks. All patients had significant anhedonia which was defined as 3 or 4 points on ≥3 items on the SHAPS \u003csup\u003e13\u003c/sup\u003e. This recruitment strategy is consistent with anhedonia as a cross-diagnostic symptom with a tentative common pathophysiology involving reward circuitry alterations and low dopaminergic activity.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eStudy participants underwent psychiatric and somatic evaluations including standard lab screening. Primary diagnoses were determined through diagnostic interviews conducted by psychiatry residents or specialists, combining relevant sections of the structured Mini International Neuropsychiatric Interview (MINI) with a review of each patient's clinical history \u003csup\u003e38\u003c/sup\u003e. All participants had ongoing treatment with one or several antidepressants or mood stabilizers ≥4 weeks and had tried at least one antidepressant at a therapeutic dose without remission. Key exclusion criteria were ongoing substance abuse, a diagnosis of\u0026nbsp;psychotic disorder, known emotionally unstable personality disorder, ADHD with hyperactivity, or impulse control disorder and acute suicidal risk. Participants were excluded if they took medications that affect pramipexole blood levels of pramipexole or have similar/antagonistic mechanisms of action as pramipexole. One exception was quetiapine ≤ 150 mg/day as the binding to dopamine receptors at such doses is low \u003csup\u003e39\u003c/sup\u003e. Full eligibility criteria are given in Supplementary Table 3.\u003c/p\u003e\n\u003ch3\u003eTrial design\u003c/h3\u003e\n\u003cp\u003eThis was an academic single-center trial conducted in Lund, Sweden from February 2023 through June 2025. \u0026nbsp;The primary outcome measure was absolute change in the SHAPS total score between baseline and week 9, calculated using the Likert scale (1–4 points per item, total scores 14 to 56). \u0026nbsp;All patients were asked to wear an accelerometer during the trial period with the option to opt out if inconvenient. An optional fMRI sub-study (at 7T) including the MID task, was conducted at baseline and week 9 in a subset of participants, who received monetary compensation for participation.\u0026nbsp;\u003c/p\u003e\n\u003ch3\u003eIntervention\u003c/h3\u003e\n\u003cp\u003eExtended release pramipexole tablets from STADA Nordic were labelled and repackaged consistent with EU guidelines and good manufacturing practice (GMP). Identical placebo tablets were produced by Ardena in line with Good Manufacturing Practice. Pramipexole tablets were taken once daily, preferable at nighttime. Patients, research physicians and nurses involved in patient assessments were blind for treatment allocation. Placebo or active treatment was placed in boxes designated for each patient by unblinded staff not involved in symptom assessments. Blinded study personnel then administrated these to the patients using flexible dosing schedule (Supplementary Table 4). Clinical Studies Sweden Forum South established the randomization list. At the week 9 visit, after clinical ratings, patients were asked if they believe they had been allocated to pramipexole or placebo. At the start of the study, participants only had two options: pramipexole or placebo. During the study, several patients described their guess as a “coin-toss”. We therefore added the possibility of answering “unsure”. \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWe used individually tailored dose titration schedule based on recommended dose escalation strategies for Parkinson’s disease but adjusted according to side effects and efficacy (see Supplementary Table 4). We increased pramipexole doses weekly and decreased the dose in the event of intolerable side effects and waited approximately one week before a new attempt of dose escalation was made. If patients had a Clinical Global Impression (CGI) – Severity score of ≤ 2, dose escalation was stopped for the remainder of the study and if patients did not have increased symptom burden at subsequent study visits.\u0026nbsp;\u003c/p\u003e\n\u003ch3\u003eAssessments\u003c/h3\u003e\n\u003ch4\u003eRating scales\u003c/h4\u003e\n\u003cp\u003eThe Snaith-Hamilton Pleasure Scale (SHAPS) \u003csup\u003e40\u003c/sup\u003e was scored from 1 to 4 on each item with a total score of 56. The SHAPS is a commonly used self-rating scale that mainly covers the consummatory phase of anhedonia. Response (≥50% reduction in SHAPS scores) was evaluated using both the Likert scoring method (1–4 points per item) and the original dichotomized method (1–2=0, 3–4=1). Remission was defined only according to the dichotomized scoring method.\u003c/p\u003e\n\u003cp\u003eWe used the self-rating version of Montgomery-Åsberg Depression Rating Scale (MADRS-S), and response was defined as ≥50% improvement and remission as ≤10 \u003csup\u003e41\u003c/sup\u003e at week 9.\u003c/p\u003e\n\u003cp\u003eThe Hamilton Depression Rating Scale – 6-item version (HDRS-6) \u003csup\u003e42\u003c/sup\u003e is an expert-rating-scale including six core depression items from the HDRS – “depressed mood”, “feelings of guilt”, “work and interest”, “psychic anxiety”, “general somatic symptoms”, and “retardation”. This subscale has shown higher sensitivity for antidepressant signals than the full HDRS \u003csup\u003e43\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eIn addition to the SHAPS, anhedonia was also evaluated using the Dimensional Anhedonia Rating Scale (DARS)\u0026nbsp;\u003csup\u003e44\u003c/sup\u003e as it includes additional anhedonia domains and separates the motivational and consummatory phases of anhedonia.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe Apathy Evaluation Scale (AES-S) is a self-rating scale evaluating apathy symptoms\u0026nbsp;which are conceptually related to anhedonia. Although this scale has mainly been used in populations with neurodegenerative disorders, it has also been used for depression \u003csup\u003e45\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eGeneralized anxiety symptoms were assessed with the Generalized Anxiety Disorder 7-item scale (GAD-7) \u003csup\u003e46\u003c/sup\u003e, a 7-item self-report scale widely validated for screening and severity rating of generalized anxiety disorder.\u003c/p\u003e\n\u003cp\u003eInsomnia symptoms were evaluated with the Insomnia Severity Index (ISI) \u003csup\u003e47\u003c/sup\u003e, a 7-item self-report measure of perceived insomnia severity and its impact on daily functioning.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eQuality of life was measured with the Brunnsviken Brief Quality of Life Scale BBQ \u003csup\u003e48\u003c/sup\u003e, a brief self-report instrument developed and validated in Sweden for assessing subjective well-being across multiple life domains.\u003c/p\u003e\n\u003ch4\u003eAccelerometry\u003c/h4\u003e\n\u003cp\u003ePhysical activity (PA) outcomes were assessed using accelerometers (ActiGraph GT3X-BT; ActiGraph, Pensacola, Florida, USA) as further described in the study protocol \u003csup\u003e37\u003c/sup\u003e. The accelerometers were initialized to sample three-dimensional acceleration data at 30 Hz, with ActiGraph’s idle sleep mode enabled. Study participants were instructed to wear the accelerometer day and night for 10 weeks in total, at the non-dominant wrist. The first week was used as a baseline measure before the intervention started. During the remaining nine weeks, raw data were extracted every third week using the Actilife software version 6.13.4 (ActiGraph LLC). The data were extracted as gt3x-files and processed in R (version 4.5.0) with the R package GGIR (version 3.2.6) as previously described \u003csup\u003e49\u003c/sup\u003e. Data were aggregated using the Euclidean Norm Minus One g (ENMO) \u003csup\u003e50\u003c/sup\u003e metric and averaged over one-second epochs. A day was considered valid if it included at least 16 hours of wear time across the full 24-hour period and covered a minimum of two-thirds of waking hours \u003csup\u003e51\u003c/sup\u003e. Non-wear and awake time were estimated using the default algorithms in GGIR \u003csup\u003e50,52\u003c/sup\u003e. Data were analyzed for weekly PA. Patients having less than four valid days during one of the weeks did not reach the valid week criteria and were excluded from PA analyses at that timepoint, consistent with established practice \u003csup\u003e14\u003c/sup\u003e. To estimate sedentary time (SED) and PA at various intensities during awake time, ENMO cut-points developed for the non-dominant wrist by Hildebrand et al. \u003csup\u003e53,54\u003c/sup\u003e were applied (SED \u0026lt;44.8 mg; light PA (LPA) 44.8-100.6 mg; moderate to vigorous PA (MVPA) \u0026gt;100.6 mg). For PA analysis, a measurement day was defined as the period from wake-up to wake-up. A configuration file with all settings used for GGIR data processing is available as Supplementary Data S1.\u003c/p\u003e\n\u003ch4\u003efMRI and Monetary Incentive Delay Task\u003c/h4\u003e\n\u003cp\u003eTo assess treatment effects on ventral striatal activity during reward anticipation, we employed a simplified Monetary Incentive Delay Task (MID) task focusing on appetitive processing \u003csup\u003e9,55,56\u003c/sup\u003e. The task design followed earlier simplified incentive delay paradigms: on each trial, participants viewed one of two cues signaling either a high (€0.50) or low (€0.01) potential reward. Reward delivery depended on response speed to a subsequent target cue, with rewards administered on 75–80% of trials.\u0026nbsp;Scans\u0026nbsp;were acquired using a 7T whole body MR scanner (Philips Achieva, Philips Medical Systems, Best, The Netherlands) using a 32-channel head coil\u0026nbsp;(Nova Medical, Wilmington, MA, USA). Anatomical 3D T1-weighted images were acquired with the following parameters (repetition time (TR)=5.0 ms, echo time (TE)=1.97 ms,\u0026nbsp;inversion time (TI)=1200 ms, shot interval=3500 ms,\u0026nbsp;Turbo factor=450, flip angle=6°, voxel size=1.0×1.0×1.0 mm3). blood-oxygen-level-dependent (BOLD) fMRI was collected using a simultaneous multi-slice echo-planar imaging (SMS-EPI) sequence with parameters (TR=1500 ms, TE=25 ms, flip angle 55°, voxel size=2.0×2.0×2.0 mm3, slice gap=0.2 mm, slices=50, multi-slice acceleration factor=2, SENSE acceleration factor=3). In addition, a FLAIR sequence (TR=6000 ms, TE=316 ms, TI=1825 ms, flip angle 55°, voxel size=1.0×1.0×1.0 mm3) was acquired and read by an experienced neuroradiologist; no relevant lesions were detected. Moderate white matter lesions believed to represent small vessel disease were present in 2 individuals (placebo 1, pramipexole 1) and more severe in 1 individual (pramipexole).\u003c/p\u003e\n\u003cp\u003ePreprocessing was performed using fMRIPrep 23.1.4 \u003csup\u003e57\u003c/sup\u003e (RRID:SCR_016216), which is based on Nipype 1.8.6 \u003csup\u003e58\u003c/sup\u003e (RRID:SCR_002502). See Supplementary Data S2 for details. Modelling of BOLD activity was performed using SPM12 (SPM12, fil.ion.ucl.ac.uk/spm/software/spm12). Volumes were first smoothed using a 6 mm FWHM Gaussian filter. First level models were then estimated for each individual and session with 6 movement parameters as well as\u0026nbsp;onsets and durations of all stimuli presentations (high-reward and low-reward cues and outcomes, target presentation and reward anticipation) convolved with the canonical haemodynamic response function from SPM12. The contrast between activity during the anticipation phase for high reward cues vs. low reward cues was used for group level analysis. For each participant, average activation statistics were extracted from a bilateral region of interest (ROI) encompassing the ventral striatum (see Fig. 3) before and after treatment. The ROI was created using the Accumbens region from the probabilistic Harvard-Oxford Subcortical Atlas. Given the spatial uncertainty of fMRI activation patterns, we chose to use a liberal definition of this brain region by employing non-thresholded ROI similar to a previous study by Krystal et al.\u0026nbsp;\u003csup\u003e21\u003c/sup\u003e.\u003c/p\u003e\n\u003ch4\u003eSafety assessments\u003c/h4\u003e\n\u003cp\u003eTo evaluate adverse events related to impulsivity, gambling behavior, and mood instability, we extracted relevant self-rating items from the QUIP \u003csup\u003e59\u003c/sup\u003e, the PGSI \u003csup\u003e60\u003c/sup\u003e, and the YMRS \u003csup\u003e61\u003c/sup\u003e. Modifications were implemented to reduce administration time and improve compatibility, and the prefix ‘M-’ was added to each scale to denote these changes. Study physicians reviewed self-ratings of these items and if there were positive responses, conducted interviews to determine if these symptoms were of clinical relevance.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eM-QUIP: The original QUIP contains four domains assessing different impulsive-compulsive behaviors. In our adaptation, the final question from each domain, specifically targeting Parkinson-related medication, was removed. Additionally, the entire fourth domain concerning hobbyism (behavioral addictions) and punding (non-goal-oriented and repetitive behaviors) was excluded. Furthermore, the response format was simplified by reducing the number of response options from five to four.\u003c/p\u003e\n\u003cp\u003eM-PGSI: In the modified PGSI, items 3, 4, 6, and 8 were omitted to avoid repetition. The remaining items were retained in their original format.\u003c/p\u003e\n\u003cp\u003eM-YMRS: The YMRS was adapted both in structure and mode of administration. Items 3, 7, 9, and 11 were excluded. Additionally, the scale was administered as a self-report rather than through clinician interview, and the number of response options per item was reduced from five to four.\u003c/p\u003e\n\u003ch3\u003eOversight\u003c/h3\u003e\n\u003cp\u003eThe study was pre-registered at clinicaltrials.gov (ref# NCT05355337). The study was approved by the Swedish Ethical Review Authority (reference number 2023-01927-02) and the Swedish Medical Products Agency (EudraCT 2022-001563-26). Clinical Studies Sweden Forum South monitored the study in accordance with Good Clinical Practice. Patients signed an informed consent form after receiving oral and written information about the study. The Department of Psychiatry at\u0026nbsp;Skåne University Hospital was sponsor.\u0026nbsp;\u003c/p\u003e\n\u003ch3\u003eStatistical Analyses\u003c/h3\u003e\n\u003cp\u003eA statistical analysis plan was uploaded at clinicaltrials.gov prior to statistical analyses. An independent statistician performed the analyses of the primary and secondary outcomes that were assessed using rating scales.\u003c/p\u003e\n\u003cp\u003eIn our power calculation, we estimated an effect size for pramipexole of 0.27, based on reports from other antidepressant studies \u003csup\u003e62\u003c/sup\u003e. This corresponds to a clinically significant MADRS score improvement of approximately 4 points, which aligns with a ≥ 4-point change on the SHAPS. We based the correlation coefficient between repeated MADRS measures on data from our previous pilot study (r = 0.5). To achieve 80% power with an alpha of .05, we initially calculated that 74 participants were necessary. Considering an estimated 5% dropout rate from our pilot data, we aimed to recruit 80 participants to start treatment. A prespecified interim analysis was conducted by an independent statistician in June 2024. The number of dropouts was controlled, and the sample size was recalculated with an updated standard deviation. Based on these results, the recruitment target was increased by five participants. 80 patients with complete efficacy data through week 9 were needed.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eStatistical analyses of longitudinal outcome data were conducted using mixed models for repeated measures, including fixed effects; treatment group (placebo vs. pramipexole), time (week), and their interaction (group × time) plus the baseline value of the respective outcome to adjust for individual differences at study entry. \u0026nbsp;The unstructured covariance structure was chosen. Hedges’ g’s effect size was calculated. The analyses were performed on data with missing values replaced by last-observation-carried forward (LOCF), but also on data with missing values.\u0026nbsp;Non-parametric correlation analyses (Spearman) were conducted to examine associations between ventral striatal activation and SHAPS change scores.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIBM SPSS Statistics version 28 and 30 (IBM Corporation, Armonk, NY, USA), SAS Enterprise Guide 8.3 with SAS Proc mixed and R (version 4.5.0) with nlme (v3.1-168) and emmeans package (v 1.11.2-8) were used. The statistical significance level was set to p \u0026lt; 0.05.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eData availability\u003c/h2\u003e\n\u003cp\u003eThe datasets generated and analyzed during this study contain sensitive personal information and are protected under the European Union General Data Protection Regulation (GDPR). For this reason, individual-level clinical data cannot be made publicly available. De-identified data that support the findings of this study may be available from the corresponding author upon reasonable request, contingent upon approval from the relevant institutional ethics committee and compliance with GDPR and local data protection regulations.\u003c/p\u003e\n\u003ch2\u003eFunding\u003c/h2\u003e\n\u003cp\u003eThe study has received funding from the Swedish Research Council (grant number 2020-01428), Swedish governmental funding of clinical research (ALF), grants from the province of Scania,\u0026nbsp;Olle Engkvist Foundation (grant number 214-0363),\u0026nbsp;the Crafoord Foundation (grant number 20220522), the Brain Foundation (FO2022-0050 \u0026amp; FO2025-0058-HK-168), Ellen and Henrik Sjöbring Foundation, Söderström – Königska Foundation (grant number SLS-969692), Region Kronoberg, Bror Gadelius Foundation, John Hains Foundation, Per-Eric and Ulla Schyberg’s Foundation, OM Persson Foundation, Foundation for Mental Health, grants from the Department of Psychiatry Skåne University Hospital, and Sten K. Johnson Foundation. This was an academic trial and funders had no role in designing or conducting the trial. \u0026nbsp;\u003c/p\u003e\n\u003ch2\u003eAcknowledgements\u003c/h2\u003e\n\u003cp\u003eWe would like to express our sincere gratitude to research coordinator Johanna Larsson and research nurses Jeanette Tindholt, Sara Helgesson, and Kajsa Jönsson for their support in participant coordination and data collection. We also thank Ann-Sofi Svensson for her invaluable assistance with study logistics and administration. We also acknowledge statistician Helene Jacobsson and data manager Andre Wennersten for their contributions to the study.\u0026nbsp;The National 7T facility at Lund University Bioimaging Center is gratefully acknowledged for providing experimental resources. We acknowledge support from Philips Clinical Science.\u003c/p\u003e\n\u003ch2\u003eDisclosures\u003c/h2\u003e\n\u003cp\u003eDr Lindqvist has received\u0026nbsp;speaking honorarium from H. Lundbeck AB and Janssen-Cilag AB.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDr Asp has received\u0026nbsp;speaking honorarium from H. Lundbeck AB.\u003c/p\u003e\n\u003cp\u003eOver the past 3 years, Dr. Pizzagalli has received consulting fees from Arrowhead Pharmaceuticals, Boehringer Ingelheim, Circular Genomics, Compass Pathways, Engrail Therapeutics, Karla Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, and Neuroscience Software; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) and Alkermes; he has received research funding from the Bird Foundation, Brain and Behavior Research Foundation, Dana Foundation, Millennium Pharmaceuticals, NIMH, and Wellcome Leap; he has received stock options from Ceretype Neuromedicine, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAll other authors have no conflicts of interest or relevant disclosures. All views expressed are solely those of the authors.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eCassano, P. \u0026amp; Fava, M. Depression and public health: an overview. \u003cem\u003eJ Psychosom Res\u003c/em\u003e \u003cstrong\u003e53\u003c/strong\u003e, 849-857 (2002).\u003c/li\u003e\n\u003cli\u003eSerretti, A. Anhedonia: Current and future treatments. \u003cem\u003ePCN Rep\u003c/em\u003e \u003cstrong\u003e4\u003c/strong\u003e, e70088 (2025).\u003c/li\u003e\n\u003cli\u003eHyman, S.E. The diagnosis of mental disorders: the problem of reification. \u003cem\u003eAnnu Rev Clin Psychol\u003c/em\u003e \u003cstrong\u003e6\u003c/strong\u003e, 155-179 (2010).\u003c/li\u003e\n\u003cli\u003eHasler, G., Drevets, W.C., Manji, H.K. \u0026amp; Charney, D.S. Discovering endophenotypes for major depression. \u003cem\u003eNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology\u003c/em\u003e \u003cstrong\u003e29\u003c/strong\u003e, 1765-1781 (2004).\u003c/li\u003e\n\u003cli\u003ePizzagalli, D.A. \u003cem\u003eAnhedonia: Preclinical, Translational, and Clinical Integration\u003c/em\u003e, (2022).\u003c/li\u003e\n\u003cli\u003ePizzagalli, D.A. Toward a Better Understanding of the Mechanisms and Pathophysiology of Anhedonia: Are We Ready for Translation? \u003cem\u003eAm J Psychiatry\u003c/em\u003e \u003cstrong\u003e179\u003c/strong\u003e, 458-469 (2022).\u003c/li\u003e\n\u003cli\u003eDer-Avakian, A. \u0026amp; Markou, A. The neurobiology of anhedonia and other reward-related deficits. \u003cem\u003eTrends Neurosci\u003c/em\u003e \u003cstrong\u003e35\u003c/strong\u003e, 68-77 (2012).\u003c/li\u003e\n\u003cli\u003eFawcett, J.\u003cem\u003e, et al.\u003c/em\u003e Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression. \u003cem\u003eAm J Psychiatry\u003c/em\u003e \u003cstrong\u003e173\u003c/strong\u003e, 107-111 (2016).\u003c/li\u003e\n\u003cli\u003eVentorp, F.\u003cem\u003e, et al.\u003c/em\u003e Preliminary Evidence of Efficacy and Target Engagement of Pramipexole in Anhedonic Depression. \u003cem\u003ePsychiatr Res Clin Pract\u003c/em\u003e \u003cstrong\u003e4\u003c/strong\u003e, 42-47 (2022).\u003c/li\u003e\n\u003cli\u003eLemke, M.R., Brecht, H.M., Koester, J., Kraus, P.H. \u0026amp; Reichmann, H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. \u003cem\u003eJ Neuropsychiatry Clin Neurosci\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e, 214-220 (2005).\u003c/li\u003e\n\u003cli\u003eChernoloz, O., El Mansari, M. \u0026amp; Blier, P. Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. \u003cem\u003eJ Psychiatry Neurosci\u003c/em\u003e \u003cstrong\u003e37\u003c/strong\u003e, 113-121 (2012).\u003c/li\u003e\n\u003cli\u003eBrowning, M.\u003cem\u003e, et al.\u003c/em\u003e Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK. \u003cem\u003eLancet Psychiatry\u003c/em\u003e (2025).\u003c/li\u003e\n\u003cli\u003eSnaith, R.P.\u003cem\u003e, et al.\u003c/em\u003e A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. \u003cem\u003eBr J Psychiatry\u003c/em\u003e \u003cstrong\u003e167\u003c/strong\u003e, 99-103 (1995).\u003c/li\u003e\n\u003cli\u003eMigueles, J.H.\u003cem\u003e, et al.\u003c/em\u003e Accelerometer Data Collection and Processing Criteria to Assess Physical Activity and Other Outcomes: A Systematic Review and Practical Considerations. \u003cem\u003eSports Med\u003c/em\u003e \u003cstrong\u003e47\u003c/strong\u003e, 1821-1845 (2017).\u003c/li\u003e\n\u003cli\u003eTreadway, M.T. \u0026amp; Salamone, J.D. Vigor, Effort-Related Aspects of Motivation and Anhedonia. \u003cem\u003eCurr Top Behav Neurosci\u003c/em\u003e \u003cstrong\u003e58\u003c/strong\u003e, 325-353 (2022).\u003c/li\u003e\n\u003cli\u003eTundo, A.\u003cem\u003e, et al.\u003c/em\u003e Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis. \u003cem\u003eLife (Basel)\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e(2023).\u003c/li\u003e\n\u003cli\u003eFerenczi, E.A.\u003cem\u003e, et al.\u003c/em\u003e Prefrontal cortical regulation of brainwide circuit dynamics and reward-related behavior. \u003cem\u003eScience\u003c/em\u003e \u003cstrong\u003e351\u003c/strong\u003e, aac9698 (2016).\u003c/li\u003e\n\u003cli\u003eHoflich, A., Michenthaler, P., Kasper, S. \u0026amp; Lanzenberger, R. Circuit Mechanisms of Reward, Anhedonia, and Depression. \u003cem\u003eInt J Neuropsychopharmacol\u003c/em\u003e \u003cstrong\u003e22\u003c/strong\u003e, 105-118 (2019).\u003c/li\u003e\n\u003cli\u003eArgyropoulos, S.V. \u0026amp; Nutt, D.J. Anhedonia revisited: is there a role for dopamine-targeting drugs for depression? \u003cem\u003eJ Psychopharmacol\u003c/em\u003e \u003cstrong\u003e27\u003c/strong\u003e, 869-877 (2013).\u003c/li\u003e\n\u003cli\u003eInsel, T.\u003cem\u003e, et al.\u003c/em\u003e Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. \u003cem\u003eAm J Psychiatry\u003c/em\u003e \u003cstrong\u003e167\u003c/strong\u003e, 748-751 (2010).\u003c/li\u003e\n\u003cli\u003eKrystal, A.D.\u003cem\u003e, et al.\u003c/em\u003e A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating kappa-opioid antagonism as a treatment for anhedonia. \u003cem\u003eNat Med\u003c/em\u003e \u003cstrong\u003e26\u003c/strong\u003e, 760-768 (2020).\u003c/li\u003e\n\u003cli\u003eMiller, A.H.\u003cem\u003e, et al.\u003c/em\u003e Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry. \u003cem\u003eBrain Behav Immun\u003c/em\u003e \u003cstrong\u003e125\u003c/strong\u003e, 319-329 (2025).\u003c/li\u003e\n\u003cli\u003eFried, E.I. Moving forward: how depression heterogeneity hinders progress in treatment and research. \u003cem\u003eExpert Rev Neurother\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e, 423-425 (2017).\u003c/li\u003e\n\u003cli\u003eWhitton, A.E. \u0026amp; Pizzagalli, D.A. Anhedonia in Depression and Bipolar Disorder. \u003cem\u003eCurr Top Behav Neurosci\u003c/em\u003e \u003cstrong\u003e58\u003c/strong\u003e, 111-127 (2022).\u003c/li\u003e\n\u003cli\u003eNutt, D.\u003cem\u003e, et al.\u003c/em\u003e The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. \u003cem\u003eJ Psychopharmacol\u003c/em\u003e \u003cstrong\u003e21\u003c/strong\u003e, 461-471 (2007).\u003c/li\u003e\n\u003cli\u003eFedor, S.\u003cem\u003e, et al.\u003c/em\u003e Wearable Technology in Clinical Practice for Depressive Disorder. \u003cem\u003eN Engl J Med\u003c/em\u003e \u003cstrong\u003e389\u003c/strong\u003e, 2457-2466 (2023).\u003c/li\u003e\n\u003cli\u003eVitale, C.\u003cem\u003e, et al.\u003c/em\u003e Exercise dependence induced by pramipexole in Parkinson's Disease-a case report. \u003cem\u003eMov Disord\u003c/em\u003e \u003cstrong\u003e25\u003c/strong\u003e, 2893-2894 (2010).\u003c/li\u003e\n\u003cli\u003eMishra, B.R.\u003cem\u003e, et al.\u003c/em\u003e Comparative efficacy of antidepressant augmentation with amantadine vs pramipexole in treatment-resistant unipolar depression: A randomised controlled trial. \u003cem\u003eJ Affect Disord\u003c/em\u003e \u003cstrong\u003e390\u003c/strong\u003e, 119891 (2025).\u003c/li\u003e\n\u003cli\u003eBerger, M.\u003cem\u003e, et al.\u003c/em\u003e Cost-effectiveness of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression: Economic evaluation of the PAX-BD randomised controlled trial. \u003cem\u003eJ Affect Disord\u003c/em\u003e \u003cstrong\u003e391\u003c/strong\u003e, 119937 (2025).\u003c/li\u003e\n\u003cli\u003eFava, M. The promise and challenges of drug repurposing in psychiatry. \u003cem\u003eWorld Psychiatry\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e, 28-29 (2018).\u003c/li\u003e\n\u003cli\u003eFranco-Chaves, J.A.\u003cem\u003e, et al.\u003c/em\u003e Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study. \u003cem\u003eJ Affect Disord\u003c/em\u003e \u003cstrong\u003e149\u003c/strong\u003e, 319-325 (2013).\u003c/li\u003e\n\u003cli\u003eCusin, C.\u003cem\u003e, et al.\u003c/em\u003e A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. \u003cem\u003eJ Clin Psychiatry\u003c/em\u003e \u003cstrong\u003e74\u003c/strong\u003e, e636-641 (2013).\u003c/li\u003e\n\u003cli\u003eWang, G.J.\u003cem\u003e, et al.\u003c/em\u003e Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. \u003cem\u003eLife Sci\u003c/em\u003e \u003cstrong\u003e56\u003c/strong\u003e, PL249-253 (1995).\u003c/li\u003e\n\u003cli\u003eMaj, J., Rogoz, Z., Skuza, G. \u0026amp; Kolodziejczyk, K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. \u003cem\u003eEur J Pharmacol\u003c/em\u003e \u003cstrong\u003e324\u003c/strong\u003e, 31-37 (1997).\u003c/li\u003e\n\u003cli\u003eKnutson, B. \u0026amp; Greer, S.M. Anticipatory affect: neural correlates and consequences for choice. \u003cem\u003ePhilos Trans R Soc Lond B Biol Sci\u003c/em\u003e \u003cstrong\u003e363\u003c/strong\u003e, 3771-3786 (2008).\u003c/li\u003e\n\u003cli\u003ePizzagalli, D.A.\u003cem\u003e, et al.\u003c/em\u003e Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. \u003cem\u003eAm J Psychiatry\u003c/em\u003e \u003cstrong\u003e166\u003c/strong\u003e, 702-710 (2009).\u003c/li\u003e\n\u003cli\u003eLindahl, J.\u003cem\u003e, et al.\u003c/em\u003e Add-on pramipexole for anhedonic depression: study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden. \u003cem\u003eBMJ Open\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e, e076900 (2023).\u003c/li\u003e\n\u003cli\u003eSheehan, D.V.\u003cem\u003e, et al.\u003c/em\u003e The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. \u003cem\u003eJ Clin Psychiatry\u003c/em\u003e \u003cstrong\u003e59 Suppl 20\u003c/strong\u003e, 22-33;quiz 34-57 (1998).\u003c/li\u003e\n\u003cli\u003eNord, M.\u003cem\u003e, et al.\u003c/em\u003e Comparison of D(2) dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. \u003cem\u003eInt J Neuropsychopharmacol\u003c/em\u003e \u003cstrong\u003e14\u003c/strong\u003e, 1357-1366 (2011).\u003c/li\u003e\n\u003cli\u003eNakonezny, P.A., Carmody, T.J., Morris, D.W., Kurian, B.T. \u0026amp; Trivedi, M.H. Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder. \u003cem\u003eInt Clin Psychopharmacol\u003c/em\u003e \u003cstrong\u003e25\u003c/strong\u003e, 328-333 (2010).\u003c/li\u003e\n\u003cli\u003eThase, M.E., Mahableshwarkar, A.R., Dragheim, M., Loft, H. \u0026amp; Vieta, E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. \u003cem\u003eEur Neuropsychopharmacol\u003c/em\u003e \u003cstrong\u003e26\u003c/strong\u003e, 979-993 (2016).\u003c/li\u003e\n\u003cli\u003eBech, P.\u003cem\u003e, et al.\u003c/em\u003e Quantitative rating of depressive states. \u003cem\u003eActa Psychiatr Scand\u003c/em\u003e \u003cstrong\u003e51\u003c/strong\u003e, 161-170 (1975).\u003c/li\u003e\n\u003cli\u003eHieronymus, F., Emilsson, J.F., Nilsson, S. \u0026amp; Eriksson, E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. \u003cem\u003eMol Psychiatry\u003c/em\u003e \u003cstrong\u003e21\u003c/strong\u003e, 523-530 (2016).\u003c/li\u003e\n\u003cli\u003eRizvi, S.J.\u003cem\u003e, et al.\u003c/em\u003e Development and validation of the Dimensional Anhedonia Rating Scale (DARS) in a community sample and individuals with major depression. \u003cem\u003ePsychiatry Res\u003c/em\u003e \u003cstrong\u003e229\u003c/strong\u003e, 109-119 (2015).\u003c/li\u003e\n\u003cli\u003eMarin, R.S., Biedrzycki, R.C. \u0026amp; Firinciogullari, S. Reliability and validity of the Apathy Evaluation Scale. \u003cem\u003ePsychiatry Res\u003c/em\u003e \u003cstrong\u003e38\u003c/strong\u003e, 143-162 (1991).\u003c/li\u003e\n\u003cli\u003eSpitzer, R.L., Kroenke, K., Williams, J.B. \u0026amp; L\u0026ouml;we, B. A brief measure for assessing generalized anxiety disorder: the GAD-7. \u003cem\u003eArch Intern Med\u003c/em\u003e \u003cstrong\u003e166\u003c/strong\u003e, 1092-1097 (2006).\u003c/li\u003e\n\u003cli\u003eBastien, C.H., Valli\u0026egrave;res, A. \u0026amp; Morin, C.M. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. \u003cem\u003eSleep Med\u003c/em\u003e \u003cstrong\u003e2\u003c/strong\u003e, 297-307 (2001).\u003c/li\u003e\n\u003cli\u003eLindner, P.\u003cem\u003e, et al.\u003c/em\u003e The Brunnsviken Brief Quality of Life Scale (BBQ): Development and Psychometric Evaluation. \u003cem\u003eCogn Behav Ther\u003c/em\u003e \u003cstrong\u003e45\u003c/strong\u003e, 182-195 (2016).\u003c/li\u003e\n\u003cli\u003eMigueles, J., Rowlands, A., Huber, F., Sabia, S. \u0026amp; van Hees, V. GGIR: A Research Community\u0026ndash;Driven Open Source R Package for Generating Physical Activity and Sleep Outcomes From Multi-Day Raw Accelerometer Data. \u003cem\u003eJournal for the Measurement of Physical Behaviour\u003c/em\u003e \u003cstrong\u003e2\u003c/strong\u003e, 188-196 (2019).\u003c/li\u003e\n\u003cli\u003evan Hees, V.T.\u003cem\u003e, et al.\u003c/em\u003e Separating movement and gravity components in an acceleration signal and implications for the assessment of human daily physical activity. \u003cem\u003ePLoS One\u003c/em\u003e \u003cstrong\u003e8\u003c/strong\u003e, e61691 (2013).\u003c/li\u003e\n\u003cli\u003eMigueles, J.H.\u003cem\u003e, et al.\u003c/em\u003e Comparability of accelerometer signal aggregation metrics across placements and dominant wrist cut points for the assessment of physical activity in adults. \u003cem\u003eSci Rep\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, 18235 (2019).\u003c/li\u003e\n\u003cli\u003evan Hees, V.T.\u003cem\u003e, et al.\u003c/em\u003e Estimating sleep parameters using an accelerometer without sleep diary. \u003cem\u003eSci Rep\u003c/em\u003e \u003cstrong\u003e8\u003c/strong\u003e, 12975 (2018).\u003c/li\u003e\n\u003cli\u003eHildebrand, M., VT, V.A.N.H., Hansen, B.H. \u0026amp; Ekelund, U. Age group comparability of raw accelerometer output from wrist- and hip-worn monitors. \u003cem\u003eMed Sci Sports Exerc\u003c/em\u003e \u003cstrong\u003e46\u003c/strong\u003e, 1816-1824 (2014).\u003c/li\u003e\n\u003cli\u003eHildebrand, M., Hansen, B.H., van Hees, V.T. \u0026amp; Ekelund, U. Evaluation of raw acceleration sedentary thresholds in children and adults. \u003cem\u003eScand J Med Sci Sports\u003c/em\u003e \u003cstrong\u003e27\u003c/strong\u003e, 1814-1823 (2017).\u003c/li\u003e\n\u003cli\u003eKnutson, B., Westdorp, A., Kaiser, E. \u0026amp; Hommer, D. FMRI visualization of brain activity during a monetary incentive delay task. \u003cem\u003eNeuroimage\u003c/em\u003e \u003cstrong\u003e12\u003c/strong\u003e, 20-27 (2000).\u003c/li\u003e\n\u003cli\u003eJensen, J.\u003cem\u003e, et al.\u003c/em\u003e Direct activation of the ventral striatum in anticipation of aversive stimuli. \u003cem\u003eNeuron\u003c/em\u003e \u003cstrong\u003e40\u003c/strong\u003e, 1251-1257 (2003).\u003c/li\u003e\n\u003cli\u003eEsteban, O.\u003cem\u003e, et al.\u003c/em\u003e fMRIPrep: a robust preprocessing pipeline for functional MRI. \u003cem\u003eNat Methods\u003c/em\u003e \u003cstrong\u003e16\u003c/strong\u003e, 111-116 (2019).\u003c/li\u003e\n\u003cli\u003eGorgolewski, K.\u003cem\u003e, et al.\u003c/em\u003e Nipype: a flexible, lightweight and extensible neuroimaging data processing framework in python. \u003cem\u003eFront Neuroinform\u003c/em\u003e \u003cstrong\u003e5\u003c/strong\u003e, 13 (2011).\u003c/li\u003e\n\u003cli\u003eWeintraub, D.\u003cem\u003e, et al.\u003c/em\u003e Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. \u003cem\u003eMov Disord\u003c/em\u003e \u003cstrong\u003e27\u003c/strong\u003e, 242-247 (2012).\u003c/li\u003e\n\u003cli\u003eFerris, J.W., H. . The Canadian Problem Gambling Index: Final Report. (Canadian Centre on Substance Abuse (CCSA), Ottawa, 2001).\u003c/li\u003e\n\u003cli\u003eYoung, R.C., Biggs, J.T., Ziegler, V.E. \u0026amp; Meyer, D.A. A rating scale for mania: reliability, validity and sensitivity. \u003cem\u003eBr J Psychiatry\u003c/em\u003e \u003cstrong\u003e133\u003c/strong\u003e, 429-435 (1978).\u003c/li\u003e\n\u003cli\u003eCipriani, A.\u003cem\u003e, et al.\u003c/em\u003e Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. \u003cem\u003eLancet\u003c/em\u003e \u003cstrong\u003e391\u003c/strong\u003e, 1357-1366 (2018).\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"nature-portfolio","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"","title":"Nature Portfolio","twitterHandle":"","acdcEnabled":false,"dfaEnabled":false,"editorialSystem":"ejp","reportingPortfolio":"","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-7887410/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7887410/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"Here, we examined the efficacy and target engagement of dopamine agonist pramipexole in treating a cross-diagnostic sample of mood disorders characterized by severe anhedonia. Patients with major depressive disorder, dysthymia or bipolar depression, all with significant anhedonia symptoms per the Snaith-Hamilton Pleasure Scale (SHAPS), were randomized to either a flexible-dose add-on of pramipexole or placebo for nine weeks. Primary outcome was change in total SHAPS score. Accelerometers were used during the study to assess treatment-associated changes in physical activity. 7-Tesla functional magnetic resonance imaging (fMRI) with the Monetary Incentive Delay task was used to investigate reward related neural response in the ventral striatum before and after treatment. Mixed models were used to investigate between-group differences in symptom improvement. In the intention-to-treat sample (pramipexole: n=41; placebo: n=41) the mean decrease in SHAPS score from baseline to week 9 in the pramipexole group was 6.5 points compared to 2.4 in the placebo group yielding a between-group difference in mean change of 4.1 (p=0.005, Hedge's g=0.63). Pramipexole was superior to placebo on several of the secondary outcomes related to anhedonia and apathy. These findings were supported by accelerometry data, which showed that pramipexole significantly increased light physical activity throughout the study, compared to placebo (p\u003c0.01, pramipexole: n=32; placebo: n=29). Adjusted mean signal intensity for reward-related activation in bilateral ventral striatum showed a significant group difference (p=0.030; Hedge's g=0.32, pramipexole: n=25; placebo: n=23). In patients receiving pramipexole (but not placebo) there was a trend suggesting that greater reductions in anhedonic symptoms were associated with increased treatment-related activation in the ventral striatum in response to reward cues. (rho=–0.38, p=0.060). Drop-out rate was 6% and the intervention was generally well tolerated with no serious adverse events. These findings demonstrate that pramipexole is an efficacious and safe add-on option for treating anhedonia in mood disorders. This treatment not only alleviates subjective symptoms of anhedonia but also objectively boosts light physical activity and increases activation in the brain's reward system. These findings suggest that pramipexole effectively targets the neurocircuits involved in motivation and reward. ClinicalTrials.gov identifier: NCT05355337.","manuscriptTitle":"Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression - the PRIME-PRAXOL randomized controlled trial","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-10-29 06:29:26","doi":"10.21203/rs.3.rs-7887410/v1","editorialEvents":[],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"nature-medicine","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"nm","sideBox":"Learn more about [Nature Medicine](http://www.nature.com/nm/)","snPcode":"","submissionUrl":"","title":"Nature Medicine","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature Research","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"7ce45d55-c367-4dee-8160-319ca380608b","owner":[],"postedDate":"October 29th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[{"id":56586791,"name":"Health sciences/Biomarkers/Predictive markers"},{"id":56586792,"name":"Health sciences/Diseases/Psychiatric disorders/Depression"},{"id":56586793,"name":"Health sciences/Health care/Therapeutics/Drug therapy/Combination drug therapy"}],"tags":[],"updatedAt":"2026-05-13T07:21:48+00:00","versionOfRecord":[],"versionCreatedAt":"2025-10-29 06:29:26","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7887410","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7887410","identity":"rs-7887410","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}